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ABSTRACT
THE ROLE OF TRANSCRIPTION FACTOR NRF2 IN THE TOXICITY OF
PERFLUOROOCTANE SULFONATE (PFOS) AND PERFLUOROOCTANOIC
ACID (PFOA) IN VITRO AND IN VIVO IN WILD-TYPE AND NRF2 DEFICIENT
C57BL/6 MICE
Saif Abdullah Alharthy

Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are
members of a family of compounds known as perfluoroalkyl substances (PFAS). This
study aimed to determine the protective role of Nrf2 against the toxicity of these agents.
Nrf2-/- and wild-type astrocytes from C57BL/6 mice were exposed to PFOS (75600µM) and PFOA (400-1000µM) for 24 hours. Lactate dehydrogenase (LDH) and
Neutral Red (NR) uptake assays showed cytotoxicity being significantly greater in nrf2/- than in the wild-type astrocytes. Concentrations of 600µM PFOS and 800µM PFOA
showed significant increases in reactive oxygen species, lipid peroxidation, and
TUNEL positive cells in both cells types with significantly higher levels in nrf2-/astrocytes as compared to wild-type astrocytes. The GSH/GSSG ratio was significantly
decreased in nrf2-/- astrocytes when compared to wild-type astrocytes. Additionally,
PFOS and PFOS caused dramatic ultrastructural alterations to the mitochondria. BHT
pretreatment in wild-type cells decreased ROS production with exposure to both agents.
Nrf2-/- and wild-type C57BL/6 male mice, were also used to address the toxicity of
PFOS and PFOA as in vivo models. Brain and liver were chosen as target organs with
the goal to assess Nrf2 involvement in each organ. 5 mg/kg PFOS and 5 mg/kg PFOA
were used to treat nrf2-/- C57BL/6 mice for 15 days and wild-type C57BL/6 mice for
30 days. Animal weights, organ weights, hematoxylin & eosin stain, trichrome stain,
GSH/GSSG ratio, 4-hydroxynonenal (4HNE), and apoptosis via using TUNEL assay
were evaluated after exposing the in vivo models to PFOS and PFOA. PFOA and PFOS

treatments resulted in toxicity in the liver with regard to the above parameters with
toxicity being significantly greater in nrf2-/- mice than WT mice. No toxicity was
detected in the hippocampus of either WT or nrf2-/- mice. Data from the current study
concludes that PFOA and PFOS are toxic to astrocytes and to the liver in C57BL/6
mice and that nrf2-/- models are more sensitive to toxicity by these agents.
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1.Introduction
1.1 Perfluoroalkyl Substances (PFAS)
Environmental pollution resulting from the introduction of toxic chemicals is a
worldwide issue. In the last few decades, concern has been raised about one of the
environmental organic pollutants, perfluoroalkyl substances. Perfluoroalkyl substances
(PFAS) are an anthropogenic class of highly fluorinated organic chemicals. A survey
done by the Organization for Economic Co-operation and Development (OECD)
showed that the Chemical Abstracts Service (CAS) registered more than 4,000
compounds classified as PFAS that are currently distributed on the global market
(Nakayama et al., 2019). Global annual PFAS emissions steadily increased from 2002
to 2012, with a geographical shift of industrial sources away from North America,
Europe and Japan towards emerging Asian economies and China (Wang et al., 2014)
Thousands of PFAS have been extensively utilized in many industrial purposes
and consumer-related applications, such as stain- and oil-resistant coatings, firefighting foams, paints, adhesives, waxes, polish, cookware and other products (Houde
et al., 2006; Renner, 2001). PFAS are composed of an aliphatic carbon backbone (4-14
carbons in length) bound to fluorine atoms instead of hydrogen atoms (Lau et al., 2007).
Consequently, high electronegativity is produced from this bond making the structures
of PFAS extremely stable and hard to biodegrade after release into the environment
(Okazoe, 2009). To date, most research attention has globally been given to two of
PFAS, perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA). These
chemicals are widely detected in the environment, wildlife, and humans (Bhavsar et al.,
2016). The chemical structure of PFOS and PFOA contains eight carbons, where each
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carbon is bound to fluorine atoms, that bind to functional groups sulfonate and
carboxylate, respectively, (Lau et al., 2004) Figure 1.

Perfluorooctane Sulfonate (PFOS)

Perfluorooctanoic Acid (PFOA)
Figure1: The chemical Structure of Perfluorooctane Sulfonate (PFOS) and
Perfluorooctanoic Acid (PFOA)

The primary global production of PFOS and PFOA was mainly by Minnesota
Mining and Manufacturing (3M) and DuPont companies in the United States. In 2000,
the estimation of PFOS and PFOA production was 3,500 tons (Wang et al., 2014).
Moreover, the total historic production of PFAS precursors was 96,000 tons and
generated about 26,500 tons of waste (Paul et al., 2010). Since 2002, the production of
PFAS has gradually been shifted to other developing countries. China in particular has
scaled up the production of PFOS considerably from an estimate of 250–300 tons per
year since 2006 (Lim et al., 2011 and Wang et al., 2014).
The widespread distribution of PFAS has elevated human exposure to the
chemicals from several sources. There were detectable levels in indoor air, clothes
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dryers, and house dust (Strynar and Lindstrom, 2008; Shoeib et al., 2011). Measurable
amounts of PFOS and PFOA were detected in food and dietary intake, such as fish,
cow’s milk and hen’s egg (Johansson et al., 2014). Additionally, vegetables (potatoes,
lettuce, tomatoes, cucumbers, cabbage), fruit, cereals, sweets and salt had been
contaminated with PFOS and PFOA (Herzke et al., 2013; Herzke et al., 2013). One of
the major sources of human exposure to PFOS and PFOA is drinking water. The
primary source of water in New York is Skaneateles Lake. PFOA and PFOS were the
two most abundant chemicals that were present in septic effluent, lake, and tap water
of several households. (USEPA, 2009b). Surface water samples from rivers/creeks and
estuaries had considerable amount of PFAS, especially PFOS and PFOA. (Zhang, X et
al, 2016). The concentrations of PFOS and PFOA have been monitored in several kinds
of organisms, such as polar bears, arctic foxes, seabirds and some sea animals
including the larger shark species, mulloway, dusky flathea, blue swimmer crab, and
prawn (Routti et al., 2017; Taylor, 2019; Costantini et al., 2019; Zafeiraki et al., 2019).
Evidence of PFAS levels in animal species have triggered researchers’ attention
to investigate the levels of PFAS in human samples. PFAS have been detected in human
blood and tissue samples from occupationally and non-occupationally exposed humans
throughout the world. Biomonitoring studies have stated that humans are ubiquitously
exposed to PFAS (Kannan et al., 2004). Contaminated foods, indoor air, dust, and
drinking water resulted in measurable amounts of PFOS and PFOA in humans (Yamada
et al., 2014; Fraser et al., 2013; Vestergren and Cousins 2009; ATSDR 2015; Emmett
et al., 2006; Hölzer et al., 2008). Additionally, occupational groups, such as firefighters
using flame-retarding foams have been shown to have levels of PFAS (Dobraca et al.,
2015; Rotander et al., 2015). The U.S. Centers for Disease Control and Prevention
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(CDC) later reported that most people in the United States have a measurable amount
of PFAS in their blood. (CDC, 2017)
The pharmacokinetic properties of PFOA and PFOS have been well studied.
Briefly, animal studies have proved that these compounds are well absorbed orally,
poorly eliminated, and not metabolized (Ophaug and Singer, 1980; Vanden Heuvel et
al., 1991). These chemicals are distributed mainly to the serum, liver, and kidney,
usually with liver concentrations being 3–5 times higher than serum concentrations in
the rat, while liver concentrations in humans and non-human primates are only 1.3–2
times higher than in serum (Hundley et al., 2006; Johnson et al., 1979; Olsen et al.,
2003). Both compounds have a high affinity for binding to albumin and to a lesser
extent, apolipotrotein B (ApoB), a lipid carrier, and liver fatty acid binding protein (Han
et al., 2003; Kerstner-Wood et al., 2003). These agents have been detected in umbilical
cord blood of humans and in breast milk, which means that they can cross the placenta
and they can reach breast milk, exposing the fetus and neonate (Apelberg et al., 2007;
Hinderliter et al., 2005)
PFOS and PFOA exhibit differences in plasma half-lives across species. The
elimination half-life for PFOA in female rats is 2-4 h, whereas it is 4-6 days in male
rats (Hanhijarvi et al., 1987; Kudo et al., 2002). This gender difference in elimination
is not observed for PFOS in rats (half-life is 30-50 days, or mice (half-life is 40 days)
(Benskin et al., 2009). Human half-lives are longer for both compounds (3-5 years)
(Butenhoff et al., 2004a; Olsen et al., 2007). The reason behind the varied elimination
across genders and species has not been conclusively investigated; however, evidence
from studies conducted on rat and human transporters showed that transporters, such as
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organic anion transporters (OATs), in the proximal tubule of the kidney may be
responsible (Kudo et al., 2002; Tan et al., 2008)
The US Environmental Protection Agency (USEPA) issued drinking water
health advisories for PFOA and PFOS at 70 ng/L each. These advisories have been
followed by some states, such as Alaska, Arizona, Alabama, Colorado, Maine,
Massachusetts, Michigan, New York, Rhode Island, and West Virginia (OCDW, 2019).
California (CSWRCB, 2019) set the levels for PFOA and PFOS at 14 ng/L and 13 ng/L,
respectively. The Minnesota health advisory levels for PFOA and PFOS are 35 ng/L
and 27 ng/L, respectively (Human Health-Based Water Guidance Table, 2019). The
New Jersey health advisory levels for PFOA and PFOS are 14 and 13 ng/L, respectively
(New Jersey Department of Environmental Protection, 2019). The proposed oral
minimal risk levels of ATSDR are 3 × 10−6 mg/kg/day for PFOA and 2 × 10−6
mg/kg/day for PFOS. Internationally, a few countries have set regulatory standards for
these chemicals. For example, Health Canada established a maximum acceptable
concentration for PFOA (Health Canada (PFOA), 2019) and PFOS (Health Canada
(PFOS), 2019) at 200 ng/L and 600 ng/L, respectively
The potential health adverse results from the exposure to these chemicals
enforced 3M to phase out PFOS in 2002, and DuPont to cease the production of PFOA
by the end of 2013 (Buck et al., 2011). Potential toxicities in animals have been well
characterized. Subchronic exposure to PFOS caused significant weight loss, reductions
in serum cholesterol and thyroid hormones, and hepatotoxicity. Repeated-dose studies
with PFOA in rodents showed induction of liver tumors, Leydig cell tumors, and
pancreatic acinar cell tumors (Biegel et al., 2001; USEPA, 2005). Human health risks
of PFOS and PFOA have also been reported. The main toxic effects of PFOS and PFOA

5

include hepatotoxicity, neurotoxicity, reproductive toxicity, immunotoxicity, thyroid
disruption, and cardiovascular toxicity (Sunderland et al., 2019).
A number of studies have examined associations between PFAS and
neurological outcomes in children, including effects on attention, behavior, motor
activity, learning, cognition, and development. In a cross-sectional study of NHANES
data observed increased odds of parent-reported attention deficit hyperactivity disorder
(ADHD) with increased serum PFOA and PFOS (Hoffman et al., 2010) Another study
by Gump, et al., (2011) found impaired response inhibition/impulsivity was associated
with increasing PFAS exposures (blood); associations with PFOA were of lower
magnitude than associations with other PFAS. Johansson, et al., (2008) demonstrated
neurobehavioral deficits, such as hyperactivity and inability to habituate, in adult mice
after neonatal PFOA and PFOS exposure
Endocrine disruption has been associated with the presence of PFAS in human.
A cross-sectional study in Taiwan examined follicle stimulating hormone levels in
association with serum PFAS in 12–17 year old, finding decreased FSH associated with
increasing PFOS in boys (Tsai et al., 2015). Experimental studies found that PFOS
treatment reduces the serum concentrations of total T4, free T4, and total T3 in pregnant
rats (Luebker et al., 2005; Thibodeaux et al 2003). In a study of 52 boys and 31 girls in
the Netherlands, increasing T4 levels in girls were associated with increasing cord
blood PFOA concentrations (DeCock et al., 2014). The relation of PFAS with chronic
kidney diseases (CKD) has been examined. Shanker et al. (2011) found that the serum
levels of PFAS were positively associated with CKD in 4,587 adult participants (51.1%
women) from the combined 1999–2000 and 2003–2008 cycles of the National Health
and Nutritional Examination Survey (Shanker et al., 2011). In rats, these compounds

6

have been also associated with hepatocellular adenomas (Lau et al., 2007). In mice,
PFAS affects the activation of the peroxisome proliferator activated receptorα (PPARα)
lipid modulation, glucose homeostasis, cell proliferation, and inflammation (Pyper et
al., 2010) A positive association between PFOA and PFOS concentration and serum
ALT levels in the C8 Health Project included 69,030 people, most of them adults (Gallo
et al., 2012).
1.2 In Vitro Model System
Astrocytes regulate a wide range of functions in the central nervous system
(CNS). They appear to be the primary defense in the CNS following exposure to
neurotoxicants (Kim et al., 2019). In the central nervous system (CNS), neuroglial cells
consist mainly of astrocytes, microglia, and oligodendrocytes. Astrocytes participate in
the formation of the blood–brain barrier (BBB) (Abbott, Ronnback, & Hansson, 2006),
production of proinflammatory cytokines, regulation of brain blood flow, regulation of
synaptic interaction, uptake of neurotransmitters, and ion homeostasis (Allen & Barres,
2009; Perez-Alvarez & Araque, 2013).
Astrocytes outnumber neurons and form the highest population of neuroglial
cells in the CNS. Accumulating evidence demonstrates that astrocytes and microglia
play a complex role in the integration of mature neurons (Gomes et al., 2001).
Astrocytes have a thread-like morphology with a small cytoplasm and perform normal
adaptive functions. Despite limited published data on the neurotoxicity of PFAS, it has
been reported that PFAS, especially PFOS and PFOA, showed neurotoxic effects in in
vitro models, such SH-SY5Y cells, human neuroblastoma cells, exposed to these agents
(Chen et al., 2014).
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1.3 In Vivo Model System
The hippocampus is one of the important regions in the brain. It is located in
the medial temporal lobe, a key region in the limbic system. The hippocampus
participates in a range of cognitive and affective functions (Barkus et al., 2010). The
hippocampal formation is composed of several subregions, which include the cornu
ammonis (CA1–4), the dentate gyrus, and the subiculum (Green, 1964). Structural and
functional deficits of the hippocampus characterize numerous neurological and
neuropsychiatric disorders, including Alzheimer's disease, anxiety disorder,
schizophrenia, and major depression (Chen & Etkin, 2013)
The CA fields contain pyramidal cells, neurons with dendrites that spread to
give the cell body a triangular appearance, as the principal excitatory cells. The CA3
region of the hippocampus contains a large excitatory recurrent collateral
network which contains the largest input source to CA3 (Cameron et al., 1993;
Markakis and Gage, 1999). The dentate gyrus is morphologically distinct from CA
fields and contains densely packed granule cells, neurons with relatively small cell
bodies. The dentate gyrus is also one of only two regions in the brain known to house
neuronal stem cells that are capable of differentiating into new neurons throughout
adulthood (Taupin, 2008). The hippocampus receives input from modulatory
neurotransmitters

including

serotonin,

norepinephrine,

and

dopamine.

The

hippocampus also receives cholinergic input from the medial septum, which regulates
the hippocampal physiological state. The medial septum is involved in setting one of
the critical oscillatory rhythms in the hippocampus. The neurogenesis in dentate gyrus
is reduced when the brain is exposed to stress (Malberg and Duman, 2003).
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The Liver is an essential organ that participates in numerous physiological
functions, such as glucose metabolism, protein synthesis, blood volume regulation,
immune system support, endocrine control of growth signaling pathways, and lipid and
cholesterol homeostasis. The liver is composed of several cell types including
hepatocytes, biliary epithelial cells (cholangiocytes), stellate cells, Kupffer cells, and
liver sinusoidal endothelial cells (Stanger, 2015). Each of these cell types possesses
unique functions that cooperatively regulate hepatic function at multiple levels. The
cells of the liver are organized around the functional structural unit of the liver — the
lobule. This consists of chords of hepatocytes organized in a typically hexagonal shape
around the central vein. At the vertices of this hexagon are the portal triads consisting
of closely grouped branches of the hepatic artery, portal vein, and bile ducts (Shetty et
al., 2018). Liver plays a critical role in detoxifying chemicals aids in protecting the
body from accumulation of most toxicants. Therefore, damage to liver will generally
result in potential adverse effects to the liver and to any other organs directly affected
by liver function.
There is evidence that that brain damage may result from interference with
supply of nutrients and that this may be a consequence of liver injury (Acker et al.,
1982). The most widely recognized aspect of this relation is that hepatocellular failure
may be complicated by the behavioral syndrome of hepatic encephalopathy, in which
neurotransmission in the brain is altered. Recently, it has been suggested that two other
behavioral complications of liver disease, scratching due to pruritus in cholestatic
patients (Bergasa et al., 1995) and profound fatigue in patients with chronic cholestasis
may also be associated with altered neurotransmission in the brain (Jones et al., 1997).
There has been an association between brain and non-alcoholic fatty liver diseases but
the mechanisms are difficult to elucidate (Weinstein et al., 2018). Several studies
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demonstrated that PFOS and PFOA exposure caused hepatotoxicity and neurotoxicity
in in vivo models, such rats or mice (Tan et al., 2013; Beggs et al., 2016; Gaballah et
al., 2020).
1.4 The Role of Nrf2-Keap1 in Oxidative Defense in Cells
NF-E2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) is
a defense system aimed to protect cells by its production of various antioxidant defense
enzymes. The system consists of interactions between Nrf2 and the Keap1, cytosolic
repressor protein. Nrf2 is the product of the NFE2L2 gene and belongs to the
cap′n′collar transcription factor family. Nrf2 was first described by Moi et al., (1994)
as an activator of β-globin gene expression, and later described as a major sensor of
oxidative stress in the cell (Itoh et al., 1999). Nrf2 contains seven functional domains
(Neh1–7) to regulate its stability and transcriptional activity. The N-terminal domain is
responsible for the interaction between Nrf2 and Keap1, while Neh1 domain, with its
basic leucine zipper motif, allows the binding of Nrf2 to the antioxidant response
element (ARE) sequence (Namani et al., 2014). Keap1, the main intracellular regulator
of Nrf2, is characterized by five domains, such as glycine repeat domains (DGR), which
is important for inhibiting Nrf2 activity. The DGR domains of the Keap1 homodimer
bind with DLG and ETGE domains in a single Nrf2 molecule. In response to oxidants,
the DLG motif in Nrf2 is released from the DGR domain in Keap1 thus blocking Nrf2
ubiquitination and degradation.
Nrf2 was extensively characterized by Yamamoto et al., (2003) who showed
that Nrf2 is a post-translationally regulated gene whose activation of the ARE is crucial
for the adaptive response to electrophiles (Kobayashi et al., 2005). Under normal
conditions, Nrf2 is sequestered by cytoplasmic Keap1 and targeted to proteasomal
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degradation (Wakabayashi et al., 2003). Under conditions of oxidative stress, the Nrf2Keap1 interaction is dissociated and Nrf2 translocated to the nucleus to heterodimerize
with Maf (musculoaponeurotic fibrosarcoma oncogene homolog) protein. These
heterodimers recognize the antioxidant response element (ARE), the enhancer
sequences present in the regulatory regions of Nrf2 target genes (Krajka-Kuźniak et al.,
2017). Nrf2 regulates the expression of hundreds of genes that encode proteins acting
as redox balancing factors, detoxifying enzymes, stress response proteins and metabolic
enzymes such as superoxide dismutase, glutathione peroxidase and reductase, catalase,
and other antioxidant molecules (Hahn et al., 2015).
Oxidative stress was first characterized by Helmut Sies (Jones and ) as “a
disturbance in the prooxidant to antioxidant balance in favor of the oxidant species,
leading to potential damage”. Oxidative stress is characterized by the lack of balance
between the occurrence of reactive oxygen/nitrogen species (ROS/RNS) and the ability
to counteract their action by the antioxidative protection systems (Sies 1991). Oxidative
stress results from an increase in ROS/RNS generation or from impairment in the
antioxidant protective ability; therefore, the endogenous systems fail to fight against
the oxidative attack. It has been determined that oxidative stress is correlated with over
100 diseases, such as neurodegenerative conditions (Parkinson, Alzheimer,
Huntington's disease and amyotrophic lateral sclerosis), cardiovascular and
inflammatory diseases (Gutteridge and Halliwell, 1993). Antioxidant is defined as the
ability of any compound to either delay or prevent the oxidation of a substrate
(Halliwell and Gutteridge, 2015). Antioxidants function by lowering oxidative stress,
DNA mutations, malignant transformations, as well as other parameters of cell damage
(Poljsak et al., 2013; Hitchonand El-Gabalawy, 2004). The defense system's capacity
against ROS can be overwhelmed, leading to injury occurrence (Godic et al., 2014).
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Redox homeostasis of the cell is ensured by its complex endogenous antioxidant
defense system, which includes endogenous antioxidant enzymes such as superoxide
dismutase, catalase, glutathione peroxidase, and non-enzymatic compounds, such as
glutathione and other proteins including ferritin, transferrin, ceruloplasmin, and even
albumin (Poljsak et al., 2013). Antioxidants can react by depleting molecular oxygen
or decreasing its local concentration, removing prooxidative metal ions, trapping
aggressive reactive oxygen species such as superoxide anion radical or hydrogen
peroxide, scavenging chain initiating radicals like hydroxyl OH., alkoxyl RO. or
peroxyl ROO., breaking the chain of a radical sequence or quenching singlet oxygen
(1O2) (Martysiak-Żurowska and Wenta, 2012).
The contribution of the Keap1-Nrf2 pathway to the homeostasis of organisms
has been demonstrated in many studies using nrf2-/- mice or cells (Kitaoka et al., 2019;
Ge et al., 2020). Nrf2 was originally identified as a key regulator of phase II
detoxication enzymes in response to electrophiles, so not surprisingly, the phenotypes
found in nrf2-/- mice reflected enhanced susceptibility to xenobiotics. The first report
on nrf2-/- mice in 1996 described no apparent abnormalities in the birth, growth, or
fertility of the nrf2-/- mice (Chan et al., 1996). Since Nrf2 was also shown to activate
oxidative stress inducible genes (Ishii et al., 2000), nrf2-/- mice were used to analyze
various pathological conditions related to oxidative stress, such as neurodegenerative
disorders (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and
amyotrophic lateral sclerosis). In mouse models of Parkinson’s disease and
Huntington’s disease, the administration of Nrf2 inducers decrease oxidative damage
in neural tissues (Kaidery et al., 2013, Stack et al., 2010). The increase in ROS and lipid
peroxidation and the damage to cell organelles, such as the mitochondria, were
associated with cells that were exposed to PFOS and PFOA. Moreover, stimulating
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Nrf2 in cells has attenuated the oxidative stress that resulted from PFOS and PFOA
exposure (Zarei et al., 2018; Bonato et al., 2020; Wen et al., 2021).
1.5 Apoptosis
Apoptosis is a fundamental and complex biological process that enables an
organism to kill and remove unwanted cells during development, normal homeostasis,
diseases, or external stimuli (Singh et al., 2019). Apoptotic cells exhibit several
biochemical modifications such as protein cleavage, protein cross-linking, DNA
breakdown, and phagocytic recognition that could be utilized as biomarkers for the
initiation of apoptosis. The mechanism of apoptosis involves a group of enzymes are
called caspases. These enzymes are present in inactive form but once activated,
apoptosis occurs. Once caspases are initially activated, there seems to be an irreversible
commitment towards cell death. Various morphological changes occur during
apoptosis, such as cell shrinkage and pyknosis are visible by light microscopy (Kerr et
al., 1972; Hacker, 2000). Extensive plasma membrane blebbing occurs followed by
karyorrhexis and separation of cell fragments into apoptotic bodies (Majino and Joris
1995). There are two major pathways for the apoptosis to start based on the signals that
received by the cells: the extrinsic pathway and the intrinsic pathway.
The extrinsic signaling pathways that initiate apoptosis involve transmembrane
receptor-mediated interactions. These involve death receptors that are members of the
tumor necrosis factor (TNF) receptor gene superfamily (Locksley et al., 2001). After
ligands bind to the receptors, the extrinsic pathway is initiated which leads to activate
the initiator caspase 8. Eventually, the later activates effector caspases 3,6, and 7
(Cohen, 1997). The intrinsic signaling pathways that initiate apoptosis involve a
diverse array of non-receptor-mediated stimuli that produce intracellular signals that
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act directly on targets within the cell and are mitochondrial initiated events (Majino and
Joris 1995). The pro-apoptotic protein Bax enters the mitochondria, mitochondrial
permeability increases and Cytochrome c is released into the cytoplasm. Cytochrome
c, apoptotic protease activating factor1 (Apaf-1), and pro-caspase 9 form an
apoptosome that activates caspase 9 which eventually activates effector caspase 3. A
number of studies have shown that a high generation of ROS accompanied with
mitochondrial dysfunction ultimately results in cell death via apoptotic mechanisms
(Sun et al., 2016; Sulimai et al., 2021). Apoptosis, as a result of the increase in ROS
with mitochondrial dysfunction, has been conclusively shown to occur after exposure
to PFOS and PFOA (Bassler et al., 2019).
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1.6 Purpose of the Study
The purpose of this study was to investigate the toxicity and the role of oxidative stress
resulting from perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)
exposure by using in vitro and in vivo models. The in vitro models were used are nrf2/- astrocytes and wild-type (WT) astrocytes from C57BL6 mice. The ability of PFOS
and PFOA to induce oxidative stress and elevate apoptosis were evaluated after nrf2-/and WT astrocytes were exposed to the agents. Several parameters were evaluated, such
as cell viability, cellular morphology, the levels of ROS, lipid peroxidation, caspase 3,
GSH/GSSG ratio, and alterations in mitochondrial ultrastructure. Additionally, the
effect of butylated hydroxytoluene (BHT), an exogenous antioxidant, was assessed for
its protective effect against the oxidative stress produced from the chemical exposure.
Nrf2-/- and WT C57BL/6 mice were also used to address the toxicity of PFOS and
PFOA as in vivo models. Based on pilot studies, brain and liver were chosen as target
organs. Brain was chosen as an accompaniment to the in vitro study to assess if effects
to hippocampus in live animals was comparable to cell culture. Liver was chosen as an
organ known to be affected by these agents with the goal to assess Nrf2 involvement in
each organ. Animal weights, hematoxylin & eosin stain, trichrome stain, GSH/GSSG
ratio, 4- hydroxynonenal (4HNE), and apoptosis were evaluated after exposing the in
vivo models to PFOS and PFOA. The levels of toxicity were compared between nrf2/- and WT models in order to evaluate the importance of Nrf2 and its protective role
against the oxidative stress resulted from PFOS and PFOA exposure.
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1.7 In vitro hypotheses
1. Exposure of nrf2-/- and WT astrocytes to perfluorooctane sulfonate (PFOS) and
perfluorooctanoic acid (PFOA) will result in cytotoxicity via oxidative stress, leading
to apoptotic cell death.
2.The toxicity of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)
in nrf2 -/- astrocytes will be significantly higher as compared to the WT astrocytes
3. The ultrastructure of the mitochondria will be altered after exposure of nrf2-/- and
WT astrocytes to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid
(PFOA).
4. Butylated hydroxytoluene (BHT) will protect the cells against perfluorooctane
sulfonate (PFOS) and perfluorooctanoic acid (PFOA) cytotoxicity.
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1.8 In vivo hypotheses
1. Exposure of nrf2-/- and WT C57BL/6 mice to perfluorooctane sulfonate (PFOS) and
perfluorooctanoic acid (PFOA) will result in hepatoxicity and neurotoxicity via
oxidative stress, leading to apoptotic cell death.
2. The toxicity of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)
in Nrf2 -/- C57BL/6 mice will be significantly higher as compared to the WT C57BL/6
mic
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1.9 Specific aims of the in vitro project
1. Assess the cell viability in

nrf2-/- and WT astrocytes after exposure to

perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by using lactate
dehydrogenase (LDH) and neutral red (NR) assays.
2. Observe the morphological alterations in nrf2-/- and WT astrocytes after exposure
to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by using
phase-contrast light microscopy.
3. Evaluate oxidative stress in nrf2-/- and WT astrocytes after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by measuring
the following biomarkers: reactive oxygen species (ROS), lipid peroxidation, the ratio
of reduced glutathione to oxidized glutathione (GSH/GSSG).
4. Examine the ultrastructure alteration to mitochondria in nrf2-/- and WT astrocytes
after exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA)
by using transmission electron microscopy (TEM).
5. Interpret apoptotic cell death in nrf2-/- and WT astrocytes after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by measuring
caspase 3 levels.
6. Visualize and quantify apoptotic cells in nrf2-/- and WT astrocytes after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by using
TUNEL assay.
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7. Determine the protective role of butylated hydroxytoluene (BHT) as an antioxidant
by measuring the levels of ROS in nrf2-/- and WT astrocytes after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) with BHT
pretreatment.
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1.10 The specific aims of the in vivo project
1. Examine the morphological alterations in brain and liver of hematoxylin and eosinstained nrf2-/- and WT C57BL/6 mice after exposure to perfluorooctane sulfonate
(PFOS) and perfluorooctanoic acid (PFOA).
2. Examine the morphological alterations and fibrosis in trichrome stained liver of nrf2/- and WT C57BL/6 mice after exposure to perfluorooctane sulfonate (PFOS) and
perfluorooctanoic acid (PFOA).
3. Evaluate oxidative stress in nrf2-/- and WT C57BL/6 mice after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by measuring
the following biomarkers: 4-hydroxynonenal (4HNE) for lipid peroxidation and the
ratio of reduced glutathione to oxidized glutathione (GSH/GSSG).
4. Interpret apoptotic cell death in nrf2-/- and WT C57BL/6 mice after exposure to
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) by using
TUNEL assay.
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2. Materials and Methods
2.1 Materials
Perfluorooctane sulfonate (PFOS; MW: 538.22), perfluorooctanoic acid
(PFOA; MW: 414.07), butylated hydroxytoluene (BHT; MW: 220.36), 2vinylpyridine, metaphosphoric acid (MPA), and GFAP Elisa kit were purchased from
Sigma-Aldrich (St. Louis, MO, U.S.A.). Dulbecco’s Modified Eagle’s Medium
(DMEM) containing L-glutamine and 15 mM HEPES and nutrient mixture F12 were
obtained from Caisson laboratories (N. Logan, UT, U.S.A.). Trypsin was obtained from
Gibco (Grand Island, NY, U.S.A.). Gentamycin, Bovine Serum Albumin (BSA), Pierce
LDH Cytotoxicity assay Kit, Neutral Red reagent, PEG 400, Microscopic silane slides,
and gavage needle (Gauge 20) were purchased from Thermo Fisher Scientific
(Rockford, IL, U.S.A. ). Dulbecco’s phosphate buffered saline (PBS), hydrochloric
acid, Triton X, dimethyl sulfoxide (DMSO), thiobarbituric acid, trichloroacetic acid,
hydrochloric acid, hydrogen peroxide (30% w/w), Bradford reagent, T75 cell culture
flasks, cell scrapers, and sterile white/black 96-well plates with clear bottoms and lids,
for luminescent/fluorescence experiments were purchased from VWR (Radnor, PA,
U.S.A.). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals
(Lawrenceville, GA, U.S.A.). GSH/GSSG-Glo Luminescence Kit was purchased from
Promega (Madison, WI ,U.S.A.). Glutathione Assay Kit was purchased from Cayman
Chemical Company (Ann Arbor, Michigan, U.S.A) 2’,7’–dichlorofluorescin diacetate
(DCFDA)- Cellular Reactive Oxygen Species (ROS) Detection Assay Kit was
purchased from Abcam (Cambridge MA, U.S.A.). Caspase-3 Colorimetric Assay Kit
was purchased from BioVision (Milpitas, CA, U.S.A.). ApopTag Plus Peroxidase in
situ apoptosis detection kit was purchased from MilliporeTM (Billerica, MA, U.S.A).
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All other reagents were obtained from reputable chemical suppliers and were of reagent
grade. Sterile plastics used were manufactured by Falcon® and Nunc®.
2.2 Animals and treatment
Male C57BL/6 wild type (WT) mice, aged 6-7 weeks and ranging from 20 to
25g body weight, were obtained from Taconic Farms and housed in the AAALAC
accredited Animal Care Center of St. John’s University. Six pairs (two males and four
females) of Nrf2 -/- mice (B6.129X1-Nfe2l2tm1Ywk/J (NRF2) knockout mice) were
obtained from Jackson Laboratory . Mice were allowed to acclimate to laboratory
conditions for a week. They were housed in an Allentown XJ® cage unit at
temperatures between 21 and 22 ◦C and humidity was maintained between 25 and 30%.
Animals were kept on a 12-h photoperiod and given food and water ad libitum. Each
mouse used was genotyped by Transnetyx (Cordova, TN). Mice were treated once a
day for 30 days with 5 mg/kg of PFOS or PFOA in 50% PEG 400 by oral gavage.
Control mice were dosed with 50% PEG 400. Following the 30 day treatment period,
mice were euthanized by decapitation. Brain and liver were removed, and were
processed for routine light microscopy and immunohistochemistry works, and some
tissues were appropriately stored at -80 freezer for biochemical analysis. All animals
were weighed prior to dosing as well as euthanization. The animal study was designed
as it is shown in Fig 2.
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C57BL/6 mice
(Nrf2-/- & Wild type)

Control group
- Vehicle: 50% v/v PEG
400/dH2O
- N= 10 mice
- Duration: once daily
for 30 day

PFOS treated group
- Dose: 5mg/kg/day
- N = 10 mice
- Duration: once daily
for 30 days

PFOA treated group
- Dose: 5mg/kg/day
- N = 10 mice
- Duration: once daily
for 30 days

24 hours after the last dose all
animals will be decapitated. Brain
(cortex & hippocampus) and liver
will be removed from all mice
Fixed tissue will be processed for
microscopic and
immunohistological studies

Frozen tissue will be used for
biochemical studies

Figure 2: The study design for nrf2-/- and WT C57BL/6
mice
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2.3 Light Microscopy
10% phosphate buffered formalin (pH 7.4) fixed tissue samples were serially
dehydrated using increasing concentrations of ethanol (70%, 80%, 90%, and 3 changes
of 100% ethanol). Following dehydration, the tissues were cleared in 2 changes of
xylene and infiltrated with 2 changes of 100% Paraplast X-TRA. The processed tissue
samples were then embedded in 100% Paraplast X-TRA using a Microm EC350
modular tissue embedded station (Microm International Inc.) and stored at 4.0 ◦C for
further use. 4-5 µm thick sections were prepared using a Leica Biocut 2030 Microtome.
Tissue sections were allowed to spread over water maintained at 37-40 ◦C, picked up
on glass slides and stained for histopathological observations. Stained tissue sections
were permounted and visualized using a Nikon Eclipse TE200-S microscope. Tissue
sections were stained following the protocol published in the ‘ Manual of Histological
Staining Methods; of the Armed Forces Institute of Pathology’ (Armed Forces institute
of Pathology and Luna, 1968).
2.4 Hematoxylin and Eosin (H&E) stain:
H&E stain is a basic screening technique for histology. Tissues were stained
with H&E for light microscopic evaluation. Two solutions were required to make the
stain: Gill’s hematoxylin solution and Eosin-Phloxine solution. The slides were
prepared as described previously, and deparaffinized in three changes of xylene (5
minutes each). They were rehydrated in decreasing ethanol concentrations (100%, 95%,
70%, and 30%) for two minutes each. The rehydrated slides were washed in distilled
water for one minute. They were then stained with hematoxylin for 10 minutes. The
slides were washed in distilled water followed by tap water for one minute each. Slides
were immersed in 1% ammonium hydroxide solution (prepared in 70% ethanol) for one
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minute, followed by a wash in tap water and then distilled water for one minute each.
The slides were placed in 70% ethanol for two minutes, followed by staining with Eosin
for one minute. Slides were dehydrated through 95% ethanol and 3 changes of 100%
ethanol for two minutes each. Finally, they were cleared in three changes of xylene for
3 minutes each.
2.5 Masson-Trichrome Stain:
Masson's Trichrome uses aniline blue as a collagen stain. The tissue section is
treated with Bouin’s solution to intensify the final color reaction. Nuclei are stained
with Weigert’s Iron hematoxylin, and cytoplasm and muscle are stained with Beibrich
scarlet-acid fuchsin. After treatment with phosphotungstic and phosphomolybdic acid,
collagen is visualized by staining with aniline blue. Rinsing in 1% glacial acetic acid
after staining provides coloring that is more delicate and transparent. Tissue is first
stained with the acid dye, Beibrich scarlet, and after treatment with phosphoric acids,
the less permeable component retains red, while the red dye is diffused out of the
collagen. Collagen binds with aniline blue to stain blue. The tissue sections were
deparaffinized in three changes of xylene (5 minutes each). They were rehydrated in
decreasing ethanol concentrations (100%, 95%, 70%, and 30%) for two minutes each.
The rehydrated slides were incubated in Bouin’s fixative at room temperature
overnight. Then, the slides were washed in running tap water until the picric acid from
Bouin’s fixative stopped eluting and were followed by rinse in distilled water. The
slides were then stained with Weigert’s iron hematoxylin followed by washing in
running tap water for ten minutes each. They were rinsed in distilled water and stained
with Beibrich Scarlet-Acid Fuchsin for 2 minutes. Then, the slides were rinsed in
distilled water and stained with phosphotungstic and phosphomolybdic acid for 10-15
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minutes. The slides were stained with aniline blue for 5 minutes and rinsed in distilled
water followed by an incubation in glacial acetic acid for 3-5 minutes. The slides were
dehydrated through 95% ethanol and 3 changes of 100% ethanol for two minutes each.
Finally, they were cleared in three changes of xylene for 3 minutes each.
2.6 Immunofluorescence (4-hydroxynonenol (4HNE))
Tissue sections were deparaffinized in three changes of xylene (5 minutes each).
They were rehydrated in decreasing ethanol concentrations (100%, 95%, 70%, and
30%) for two minutes each. Slides were washed with phosphate buffered saline (PBSpH 7.4). Then, the slides were treated with proteinase K for 15 minutes at room
temperature, followed by washing twice in Tris Buffered Saline 1×, 0.02% Tween 20
(TBS-T) and were incubated in TBS-T, 10% normal goat serum (NGS) at room
temperature for 2 hours. Tissue sections were incubated overnight at 4 ◦C with the
primary antibodies diluted in TBS-T, 1% NGS (1:200). They were washed twice in
TBS-T and incubated at room temperature for 1 hour with the secondary antibodies
diluted in TBS-T, 1% NGS (1:1000). Slides were developed with diaminobenzidine
(DAB) detection system as indicated by a brown precipitate. The slides then were
counterstained with hematoxylin for ten minutes. Slides were dehydrated through 95%
ethanol and 3 changes of 100% ethanol for two minutes each. Finally, they were cleared
in three changes of xylene for 3 minutes each.
2.7 Glutathione Assay
Brain or liver rinsed with a PBS (phosphate buffered saline) solution, pH 7.4, to remove
any red blood cells and clots. The tissues were homogenized in 1 ml of cold phosphate
buffer (pH 7.4). The homogenized tissues were centrifuged at 10,000 x g for 15 minutes
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at 4°C. Supernatant was removed and store on ice. The supernatant was deproteinated
by using 5% metaphosphoric acid (MPA). An equal volume of the MPA Reagent was
added to the sample and mixed by vortexing. The mixture was allowed to stand at room
temperature for five minutes and centrifuged at >2,000g for at least two minutes. The
supernatant was removed to a new microtube and stored at -20°C until used for assay
(The sample is stable for at least six months). This assay measures the total glutathione
(reduced + oxidized) and oxidized glutathione (GSSG). Both products (total and
oxidized glutathione) were measured simultaneously to exclude any disturbances to the
levels of both molecules. The samples were divided into two samples, one for
measuring oxidized glutathione (GSSG) and the other for measuring the total
glutathione (reduced and oxidized glutathione). For the GSSG samples,

2-

vinylpyridine solution was first prepared in ethanol by mixing 108 μL of 2vinylpyridine and 892 μL of ethanol and then 10 μL of the 2-vinylpyridine solution
were added to mL of the GSSG sample. Also, GSSG standard was provided by the
assay kit and prepared based on the assay protocol with 5 uL of 2-vinylpyridine added
per standard tube. After adding 2-vinylpyridine to the GSSG samples and standards,
the microtubes were mixed well on a vortex mixer and incubated at room temperature
for 60 minutes. Meanwhile, Triethanolamine reagent (TEAM) was prepared in water
by mixing 531 μL of triethanolamine with 469 μL of water. Total glutathione samples
and the standards were prepared by transferring the required amounts to new
microtubes (as directed by the assay protocol). Once the incubation time for the GSSG
samples was complete, 50 μL of the prepared TEAM reagent were added to all samples
and standards. After adding TEAM reagent, the samples were mixed via vortex. The
Assay Cocktail was prepared (based on the assay protocol) before transferring samples
to the wells. Then, 50 μL of the samples and standards were transferred to 96-well plate.

27

150 μL of the freshly prepared Assay Cocktail were added to each of the wells
containing standards and samples using a multichannel pipette. The plate was measured
spectrophotometrically in a BioRad microplate spectrophotometer at a wavelength of
405 nm after 25 minutes
2.8 Cell Culture and Treatments
Wild-type C57Bl/6 and nrf2-/- C57Bl/6 mice were obtained from Taconic
Farms and RIKEN BioResource Center (Tsukuba, Japan), respectively. Wild type
astrocytes and nrf2-/- astrocytes were isolated from WT C57Bl/6 and nrf2-/- C57Bl/6
mice pups (day 1 post-partum), respectively by Dr. Louis Trombetta (St. John’s
University, Queens, NY). The PCR protocol from RIKEN Center was used to confirm
knockdown of the nrf2 gene in nrf2-/- astrocytes. Astrocytes were tested for glial
fibrillary acidic protein (GFAP), an astrocytic biomarker, by ELISA assay, to confirm
astrocytic linage. The cells were cultured in Dulbecco's Modified Eagle's Medium
(DMEM)/ Ham’s F12, containing 10% v/v fetal bovine serum and 0.1% v/v gentamicin
(complete media) and maintained in 8% CO2/70-80% humidity at 37°C. Cells were
harvested at 90-95% confluency by trypsinizing for 1 min at 37°C with 0.25% v/v
trypsin in PBS. For experiments, only cell cultures ranging from passage 14 to 20 were
used. The solutions of the chemicals were prepared immediately before use in DMSO
and then diluted to appropriate concentrations in serum-free media. The final DMSO
concentration never exceeded 0.1% v/v.
2.9 Protein Assay
Cells were homogenized by 3 cycles of snap-freezing with liquid nitrogen and
thawing in a room temperature water bath. The lysate was centrifuged at 4°C for 10
minutes at 10,000x g in an Eppendorf 5804R 15-amp refrigerated centrifuge (Hamburg,
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Germany). Supernatant was transferred to a new pre-cooled microcentrifuge tube for
protein determination via using the Bradford assay. A standard curve with known
protein concentrations was developed and concentrations of unknown samples were
extrapolated using this curve.
2.10 Cytotoxicity Evaluation
2.10.1 Lactate Dehydrogenase (LDH) Assay
The viability of control and treated astrocytes (wild type & nrf2-/-) was determined by
using the lactate dehydrogenase (LDH) assay. LDH is a cytosolic enzyme present in
many different cell types, the release of which has been used as a measure of cell death.
Astrocytes were plated in 96-well plate and cultured at density of 10,000 cells/well and
exposed to 75-600 µM PFOS or 400-1000 µM PFOA for 24 hours. The media into
which LDH was released was transferred to another 96-well plate and mixed with
Reaction Mixture (provided in kit). After a 30 minute room temperature incubation,
Stop Solution (provided in kit) was added to stop the reaction. Extracellular LDH in the
media can be quantified by a coupled enzymatic reaction in which LDH catalyzes the
conversion of lactate to pyruvate via NAD+ reduction to NADH. Diaphorase then uses
NADH to reduce a tetrazolium salt (INT) to a red formazan product that can be
measured at 490nm. The formation of red formazan product was measured
spectrophotometrically in a BioRad microplate spectrophotometer at a wavelength of
490 nm. The level of formazan formation is directly proportional to the amount of LDH
released into the medium, which is indicative of cytotoxicity. LDH concentration in
control and treated samples were calculated using the following equation from provided
in the kit’s protocol:
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2.10.2 Neutral Red Assay
The Neutral Red Assay is another viability assay used to evaluate the cytotoxicity of
PFOS and PFOA in astrocytes (wild type & nrf2-/-). The required reagents for this
assay were prepared as follows. Neutral red stock solution was prepared by dissolving
40 mg neutral red dye in 10 ml PBS (calcium and magnesium free, pH 7.4).The solution
can be stored up to 2 months at room temperature (20–30 1C) if protected from light
by foil. Neutral red medium (40 ug/mL) was prepared under sterile conditions by
diluting 1:100 the neutral red stock solution with culture medium, that is, 12 ml of
medium plus 0.12 ml of the stock solution per plate. The neutral red medium was
prepared a day before and incubated overnight at cell culture temperature. Neutral red
destain solution was prepared by mixing 50% of ethanol 96%, 49% deionized water,
and 1% glacial acetic acid. The required volumes were 10 mL water, 10 mL ethanol
96% and 0.2 mL glacial acetic acid. Astrocytes were plated in 96-well plate and
cultured at density of 10,000 cells/well and exposed to 75-600 µM PFOS or 400-1000
µM PFOA for 24 hours. Neutral red working solution was prepared and incubated
overnight at the same temperature as the cells. After 24 hours incubation, the working
solution was centrifuged for 10 minutes at 600g (1,800 rpm) to remove any precipitated
dye crystals. The media was decanted from cells and 100 mL of neutral red medium
was added to each well of the plate. The plate was incubated for 2 hours. After
incubation, the neutral red media was removed and the cells were washed with 150 µL
PBS. 150 mL neutral red destain solution were added to all wells. the plate was shaken
rapidly on a microtiter plate shaker for at least 10 minutes, or until the neutral red was
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extracted from the cells and formed a homogeneous solution. The neutral red extract
was measured spectrophotometrically in a BioRad microplate spectrophotometer at a
wavelength of 550 nm.
2.11 Phase-Contrast Light Microscopy
Astrocytes were seeded at initial density of 200,000 cells in T75 flasks and
incubated to attain 90-95% confluency. Control and treatments 75 µM or 600 µM
concentrations of PFOS or 400 µM or 800 µM concentrations of PFOA were carried
out in serum-free media. After 24 hours incubation, T75 flasks were rinsed with PBS
to remove non-adherent cells. The adherent cells were viewed with a phase-contrast
Nikon Eclipse TS100 inverted light microscope and photographed.
2.12 Measurement of caspase 3 activity
Caspase 3 activity was determined using a caspase 3 activity assay kit, according to the
manufacturer's instructions (Biovision, Inc., Milpitas, CA, USA). Cells were grown and
exposed to agents as described in the cell treatment section. The media were removed
and the cells were then lysed in caspase 3 sample lysis buffer, and normalized to protein
concentration. The cell lysates were then exposed to the DEVD substrate conjugate
provided in the kit for 1 h at 37°C. The addition of a caspase-specific peptide (DEVD)
that is conjugated to the color reporter molecule p nitroaniline (pNA) is used to test the
activity of caspase 3. The cleavage of the peptide by the caspase releases the
chromophore pNA, which can be quantitated spectrophotometrically at a wavelength
of 405 nm. The absorbance of the samples was measured in a BioRad microplate
spectrophotometer at a wavelength of 405 nm.
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2.13 Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL)
Staining
TUNEL staining was performed using an ApopTag® Peroxidase in Situ
Apoptosis Detection Kit that was purchased from Millipore TM (Billerica, MA, USA).
The cells were seeded in BD Falcon chamber glass slides (4 chambers per slide) at
density of 5x104. The cells were exposed to serum-free media, 600 µM PFOS, or 800
µM PFOA for 18 hours. Afterward, the following steps of washing, fixation,
permeabilization, staining were carried out according to the manufacturer’s protocol.
Tissue slides were deparaffinized and rehydrated by moving the tissue slides through
three xylene jars (5 mintues each), two 100% ethanol jars (5 minutes each), one jar of
95% and 70% ethanol (3 minutes each), then the slides were washed with phosphate
buffered saline (PBS-pH 7.4). The slides were treated with proteinase K for 15 minutes
at room temperature, followed by washing twice in distilled water for 2 minutes. The
following steps of the assay are similar for both cells and tissue slides. Briefly,
cells/slides were treated with equilibrium buffer for at least 10 seconds. Cells/slides
were incubated with deoxynucleotidal transferase (TdT) (1 hours in humidifying
chamber at 37°C) and peroxidase-conjugated anti-digoxigenin antibody at 37°C for 30
minutes. Positive TUNEL staining was developed with diaminobenzidine (DAB)
detection system that reacts with the peroxidase and produces permanent, intensed, and
localized brown precipitate. The cells/slides were counterstained with hematoxylin and
visualized using a Nikon Eclipse TE200-S microscope. Images were captured at 20x
microscopic magnification for quantification. Representative images captured at 20x
magnification are presented in results. The positive cells were blindly counted by two
individuals in 20 random fields of 20x microscopic magnification.
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2.14 DCFDA Cellular Reactive Oxygen Species (ROS) Detection Assay
Cells were seeded in black 96-well plate with clear bottom and lid at density of
15,000 cells and treated with serum-free media, Tert-Butyl Hydrogen Peroxide
(TBHP), PFOS or PFOA at the concentrations previously described, for 24 hours.
TBHP is a solution provided by the kit as a positive control for ROS generation. 200
µM TBHP was used in the experiment. 25 μM DCFDA (a fluorescent dye) was added
to each sample and incubated at 37°C for 45 minutes. This cell permeable reagent 2’,7’–
dichlorofluorescin diacetate (DCFDA), a fluorogenic dye, measures ROS activity
within the cell. After diffusion into the cell, DCFDA is deacetylated by cellular
esterases to a non- fluorescent compound, which was later oxidized by ROS into 2’, 7’
– dichlorofluorescein (DCF). DCF is a highly fluorescent compound which can be
detected by fluorescent spectroscopy (Glo Max Detection System, Promega, Madison
WI, U.S.A.) with maximum excitation of 495 nm and emission spectra of 510-570 nm
(DCFDA/H2DCFDA-Cellular ROS Assay Kit, Abcam, Cambridge MA, U.S.A.). To
determine if the oxidant formation was able to be reduced, cells were pretreated with
butylated hydroxytoluene (BHT) 24 hours prior to PFOS and PFOA treatment. The
DCFDA assay was then carried out as previously described.
2.15 GSH/GSSG-Glo Glutathione Assay
Reduced and oxidized glutathione levels were detected via GSH/GSSG assay
(GSH/GSSG-GloTM Assay, Promega, Madison WI, U.S.A.). The cells were seeded in
clear bottom, white-walled 96-well plates at a density of 15,000 cells/well. The cells
were exposed to serum-free media, PFOS (75 µM or 600 µM), and PFOA (400 µM or
800 µM) for 24 hours. The assay is a luminescence-based system that detects and
quantifies total (GSH+GSSG) glutathione and oxidized (GSSG) glutathione. The ratios
of reduced and oxidized (GSH/GSSG) glutathione in cultured cells were calculated
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based on the provided formula in the kit’s protocol. Following treatment, media was
removed from all wells and 50 µL of total glutathione lysis reagent or oxidized
glutathione lysis reagent were added to corresponding wells for the measurement of
both total glutathione and oxidized glutathione. Luciferin generation reagent (50 µL)
was added and the plate was shaken briefly and incubated for 30 minutes at room
temperature. Finally, 100 µL of the luciferin detection reagent were added to all wells,
shaken, and incubated for 15 minutes at room temperature. The luminescence signal
was read in a Glo Max Detection System (Promega). The ratio of GSH/GSSG was
obtained by dividing the net relative luminescence units (RLU) of reduced glutathione
by the net RLU of oxidized glutathione. Results were expressed as GSH/GSSG ratio.
2.16 Thiobarbituric Acid Reactive Substances (TBARS) Assay
Mouse hippocampal astrocytes were seeded in T75 flasks until reaching 9095% confluency. Six groups were included: control (serum-free media), H2O2 (2.5
mM), PFOS (75 µM or 600 µM), or PFOA (400 µM or 800 µM) for 24 hours. Cells
were harvested and homogenized for protein determination. 400 µL of each cell
homogenate were added to 800 µL of TBARS reagent and incubated in a 95°C water
bath for 60 minutes. Samples were then cooled down on ice and transferred to a clear
flat-bottom 96-well plates. Absorbances were read at 540 nm by using Glo Max
Detection System (Promega). The absorbance of TBARS level in the samples was
quantified by using a standard curve prepared from serial dilutions of malondialdehyde
(MDA), and the results were expressed as nM of MDA per µg of protein (Fraga et al.
1988).
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2.17 Transmission Electron Microscopy (TEM)
Astrocytes were seeded in T75 flasks and incubated to reach 90-95%
confluency. The vehicle control astrocytes of wild-typed or nrf2-/- C57Bl/6 were
exposed to serum-free media and the treated groups were exposed to high
concentrations of PFOS (600 µM) or PFOA (800 µM). After 24 hours incubation, flasks
were rinsed with Sørensen’s phosphate buffer (pH 7.4) and subsequently fixed in 1.5%
v/v glutaraldehyde at 4°C for 1 h. Cells were collected in 15 mL tubes and post-fixed
in 1% w/v OsO4 prepared in Sørensen’s phosphate buffer (pH 7.4), dehydrated with
increasing concentration (30%, 60%, 90%, 100%) of acetone, and then serially
infiltrated with 50%, 100%, 100% LX112-Araldite plastic mixtures containing DDSA,
EM Bed 812, Araldite 6005, DMP (Ted Pella Inc, CA; USA). The infiltrated cells were
embedded in BEEM capsules and placed in a 60°C oven until polymerized, for
approximately four days. The embedded cells were sectioned into ultrathin section (40
nm) using a Leica EM UC6 ultramicrotome. The sections were placed on copper grids
(200 mesh), stained with uranyl acetate and lead citrate, and the micrographs were
viewed and captured using transmission electron microscope (JEOL JEM-1200EX) at
80kV.
2.18 Statistical Analysis
GraphPad Prism® v.5 software was used to analyze the data. Statistical
significance was tested for all assays using two-way analysis of variance (ANOVA)
followed by Bonferroni post-hoc test and one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparisons post-hoc test. The criterion for significance
was set at p < 0.05.
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3. Results
3.1 In Vitro Results
3.1.1 Cytotoxicity Evaluation
3.1.1.1 Cytotoxic effect of PFOS and PFOA in nrf2-/- and WT astrocytes using
the Lactate Dehydrogenase (LDH) Assay
The LDH cytotoxicity assay was used to assess the cytotoxicity of PFOS and
PFOA in nrf2-/- and WT astrocytes. Cultured cells grown to 90-95% confluency were
incubated with various concentrations of each compound, PFOS (75-600 µM) or PFOA
(400-1000 µM) for 24h. Significant cytotoxicity as indicated by release of LDH in the
media was observed from 150–600 µM for PFOS or 800-1000 µM for PFOA in nrf2/- astrocytes as compared to the control nrf2-/- astrocytes (Fig. 3). The cytotoxicity in
WT astrocytes was significantly increased at doses of 300-600 µM PFOS or 800-1000
µM PFOA as compared to control WT astrocytes as indicted by release of LDH into
the media (Fig. 3). There was no significant difference observed at the 75 µM PFOS or
400-600 µM PFOA treatments in nrf2-/- astrocytes or in the 75-150 µM PFOS or 400600 µM PFOA treatments in WT astrocytes. The cytotoxicity in nrf2-/- astrocytes
treated with 150–600 µM PFOS or 800-1000 µM PFOA was significantly higher as
compared to the respective treatments in WT astrocytes (Fig. 3).
3.1.1.2 Cytotoxic effect of PFOS and PFOA using neutral red assay
Neutral red assay is based on the ability of viable cells to incorporate and bind
the supravital dye neutral red. This weakly cationic dye penetrates cell membranes by
nonionic passive diffusion and concentrates in the lysosomes, where it binds by
electrostatic hydrophobic bonds to anionic and/ or phosphate groups of the lysosomal
matrix . The dye is then extracted from the viable cells using an acidified ethanol
solution, and the absorbance of the solubilized dye is quantified using a
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spectrophotometer. According to the data obtained from the neutral red assay, the
neutral red uptake in nrf2-/- was significantly decreased in 150–600 µM for PFOS or
800-1000 µM for PFOA as compared to control nrf2-/- astrocytes (Fig. 4). WT
astrocytes exposed to 150–600 µM PFOS or 800-1000 µM PFOA showed significantly
decreased neutral red uptake as compared to the control WT astrocytes (Fig. 4). There
was no significance differences observed in 75 µM PFOS or 400-600 µM PFOA treated
nrf2-/- astrocytes or in 75µM PFOS or 400-600 µM PFOA treated WT astrocytes. The
reduction in neutral red uptake in nrf2-/- astrocytes treated with 150–600 µM PFOS or
800-1000 µM PFOA was significantly higher as compared to the respective WT
astrocytes (Fig. 4).

3.1.2 Phase contrast light micrography of nrf2-/- and WT astrocytes treated with
PFOS and PFOA
The morphology of nrf2-/- and WT astrocytes after 24h of PFOS and PFOA
treatment was examined under phase contrast light microscopy. Control nrf2 -/- and
WT astrocytes appeared evenly distributed on the culture field with normal
morphology, such as typical fusiform cells with elongated projections and well-defined
nuclei (Fig. 5A & 6A). Phase contrast light micrographs of nrf2-/- and WT astrocytes
treated with PFOS (75 or 600 µM) or PFOA (400 or 800 µM) for 24h were displayed
in Fig 5 & 6. Cells that were treated with 75 µM PFOS showed no morphological
alterations (Fig. 5B). However, in Fig. 4C it was observed that nrf2-/- and WT
astrocytes treated 600 µM PFOS have alterations in cellular morphology, such as
rounding of cells and retraction of their cell processes and the presences of cell debris
(Fig. 5C). Fig. 6B shows that nrf2-/- and WT astrocytes treated 400 µM PFOA have no
morphological alterations. However, Fig. 6C demonstrates that nrf2-/- and WT
astrocytes treated 800 µM PFOA have alterations in cellular morphology, such as
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rounded cells with retraction of cell processes and cells debris resulted in obvious visual
reduction in cell density that is consistent with the decreases in the viability assays’
results
3.1.3 Caspase 3 activity
The activation of effector caspase 3 is a sensitive indicator of cell death via
apoptosis. The mechanism of cell death was determined by measuring the activity of
caspase 3 in nrf2-/- and WT astrocytes after 24h exposure to PFOS and PFOA. Fig. 7A
& B show that the activity of caspase 3 was significantly elevated in nrf2-/- and WT
astrocytes treated with 600 µM PFOS or 800 µM PFOA as compared to control nrf2-/and WT astrocytes. However, the activities of caspase 3 were not significantly different
from the controls after exposing both cells to low concentrations of PFOS (75 µM ) or
PFOA (400 µM) (Fig. 7A & B). After exposure to 600 µM PFOS or 800 µM PFOA,
nrf2-/- astrocytes showed significantly increased caspase 3 activities as compared to
the respective WT astrocytes (Fig. 7A & B).
3.1.4 TUNEL Assay
Nrf2-/- astrocytes exhibited poor adherence to chambers with 24h chemical
exposure. Therefore, the time period of chemical exposure had been lowered to 18
hours in order to pursue the experiment while maintaining cell adherence. Apoptotic
cells were visualized and quantified via using the TUNEL assay. The high
concentrations of PFOS (600 µM) or PFOA (800 µM) resulted in significant numbers
of positive apoptotic cells that were indicated by the black arrow (Fig. 8). While cells
undergo the process of apoptosis, DNA fragments are produced which stain with DAB
to produce a brown permanent stain as observed in Fig. 8. Fig. 9 represents a positive
control (female rodent mammary gland) that was carried out with the TUNEL assay.
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Fig. 10 shows that the apoptotic cell number in PFOS (600 µM) or PFOA (800 µM)
treated nrf2-/- and WT astrocytes were significantly higher than the controls. The
apoptotic cells were significantly higher in PFOS (600 µM) or PFOA (800 µM) treated
nrf2-/- astrocytes as compared to respective treated WT astrocytes (Fig. 10).
3.1.5 Reactive Oxygen Species (ROS)
After 24h exposure to PFOS (75 or 600 µM) or PFOA (400 or 800 µM), the
ROS levels were significantly higher in 600 µM PFOS or 800 µM PFOA treated nrf2/- and WT astrocytes while the low concentrations of both chemicals did not show
differences as compared to the controls (Fig. 11). PFOS (600 µM) or PFOA (800 µM)
treated nrf2-/- astrocytes showed significantly higher levels of ROS as compared to the
respective WT astrocytes (Fig. 11). 200 µM TBHP was used in the experiment as a
positive control (Fig. 11).
3.1.5.1 Butylated Hydroxytoluene (BHT) pretreatment in nrf2-/- and WT
astrocytes against the oxidative stress after PFOS and PFOA exposure
WT astrocytes were pretreated with BHT for 24hrs. prior to treatment with
PFOS (300 µM) or PFOA (800 µM). ROS levels were significantly lowered as
compared the PFOS (300 µM) or PFOA (800 µM) treated groups without BHT
pretreatment (Fig. 12A & B). However, nrf2-/- astrocytes was treated with PFOS (300
µM) or PFOA (800 µM) after BHT pretreatment and there were no significant
differences as compare to the PFOS (300 µM) or PFOA (800 µM) treated group without
BHT (Fig. 12A & B).
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3.1.6 Lipid Peroxidation
The occurrence of lipid peroxidation end products was confirmed by the
detection of TBARS levels in nrf2-/- and WT astrocytes treated with PFOS (75 or 600
µM) or PFOA (400 or 800 µM) for 24h. For the current work, the lipid peroxidation
levels were significantly higher in 600 µM PFOS or 800 µM PFOA treated nrf2-/- and
WT astrocytes while the low concentrations of both chemicals did not show significant
differences as compared to the controls (Fig. 13). PFOS (600 µM) or PFOA (800 µM)
treated nrf2-/- astrocytes showed significantly higher levels of lipid peroxidation as
compared to the respective WT astrocytes (Fig. 13). Hydrogen peroxide was used in
the experiment as a positive control and showed significant increases in lipid
peroxidation levels in nrf2-/- astrocytes as compared to the respective WT astrocytes.
3.1.7 GSH/GSSG Ratio
The disturbances to GSH/GSSG ratio is an indicator of oxidative stress, as GSH
binds to reactive compounds and coverts to the disulfide form. Therefore, to determine
if PFOS and PFOA exposure in nrf2-/- and WT astrocytes resulted in formation of
oxidative species that might result in alterations in GSH/GSSG ratios, cells were
exposed to PFOS (75 or 600 µM) or PFOA (400 or 800 µM) for 24h. Total glutathione
(reduced and oxidized glutathione) and oxidized glutathione levels were measured, and
the ratio was calculated. Fig. 14 demonstrates that treatment of nrf2-/- and WT
astrocytes with PFOS (600 µM) or PFOA (800 µM) caused significant decreases in the
GSH/GSSG ratios when compared to control cells, while the low concentrations of both
chemicals showed no differences. Additionally, PFOS (600 µM) or PFOA (800 µM)
treated nrf2-/- astrocytes showed significantly decreased levels in GSH/GSSG ratio as
compared to the respective WT astrocytes (Fig. 14).
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3.1.8 Transmission Electron Microscopy (TEM)
TEM was used to investigate ultrastructural mitochondrial alterations after
exposure to 600 µM PFOS or 800 µM PFOA in nrf2-/- and WT astrocytes. Figs. 15 &
16 clearly display the micrographs of control nrf2-/- and WT astrocytes that have
normal mitochondria with characteristic shape and intact and well-defined cristae. After
treatment with PFOA and PFOS in nrf2-/- and WT astrocytes, there are dramatic
alterations that can be observed in these cells. Mitochondria are grossly swollen with a
complete loss of cristae after PFOS and PFOA treatment (Figs. 15 & 16).
3.2 In Vivo Results
3.2.1 Animal and Organ Weights
Animal body and organ weight were measured. During the 30-day period of
dosing, the weight of control WT group and the WT groups treated with 5 mg/kg PFOS
or 5 mg/kg PFOA had been observed and measured daily (Fig 17B). There were no
significant differences between the control and the treated WT groups. However, nrf2/- mice were dosed for 15 days and the animals started to dramatically lose weight
between day 11and 15 (Fig. 17A). Therefore, nrf2-/- mice were euthanized on the day
16. PFOS and PFOA treated nrf2-/- mice showed significant decreases in their weights
as compared to the control nrf2-/- mice (Fig. 17A). Liver mass was significantly
increased in PFOS and PFOA treated WT liver as compared to control WT liver (Fig.
18B). However, only PFOA treated nrf2-/- liver showed significant increases as
compared to the control nrf2-/- liver (Fig. 18A). Additionally, the brain of nrf2-/- and
WT mice were weighed and there was no significant difference between the control
groups and the treated groups of both animal models (Fig. 19)
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3.2.2 Liver Microscopy: Hematoxylin and Eosin Staining
Light microscopy was used to observe liver tissues of PFOS and PFOA treated
groups and those of the control mice that were stained with hematoxylin and eosin stain.
Control liver of nrf2-/- and WT mice were morphologically characteristic
demonstrating hepatocytes and sinusoids there were well-defined and portal triads that
were intact (Fig. 20). However, the liver of PFOS (5 mg/kg) and PFOA (5 mg/kg)
treated nrf2-/- (15 days of treatment) and WT (30 days of treatment) mice showed
obvious morphological alterations, such as cytoplasmic vacuolation, hepatocellular
hypertrophy, round cytoplasmic inclusions, hemosiderin accumulation (slight brown
pigmentation), and inflammatory cells infiltration (Fig. 21 & 22).
3.2.3 Liver Microscopy: Trichrome Staining
Trichrome stain was used to detect fibrosis in liver tissues. Liver tissues of
PFOS and PFOA treated groups and those of the control mice that were stained with
trichrome stain were visualized. Control nrf2-/- and WT liver were morphologically
characteristic of normal tissue demonstrating hepatocytes and sinusoids that were welldefined and an intact portal triad (Fig. 23). However, the liver tissues of PFOS and
PFOA treated nrf2-/- and WT mice showed fibrosis around the portal triad and central
vein with some morphological alterations such as cytoplasmic vacuolation,
hepatocellular hypertrophy, dead cells, hemosiderin accumulation (slight brown
pigmentation), and inflammatory cells infiltration (Fig. 24 & 25).

3.2.4 TUNEL Staining of Liver Tissue
Apoptotic cells were visualized in liver tissues and quantified via using the
TUNEL assay. The control nrf2-/- and WT mice appeared normal and no indication of
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positive apoptotic cells were observed (Fig. 26). 5 mg/kg PFOS and 5 mg/kg PFOA
treated nrf2-/- and WT animals showed positive apoptotic cells (Fig. 27 & 28). PFOA
treated nrf2-/- group was the only group that showed significant increases in positive
apoptotic cells as compare to control nrf2-/- and to the respective WT group (Fig. 29).
Apoptotic cells were quantified by blindly counting TUNEL positive cells in 10 random
fields at 40x by two independent counters.
3.2.5 Lipid peroxidation : 4HNE staining of Liver Tissue
The lipid-aldehyde, 4-HNE, represents one of the primary by-products of lipid
peroxidation cascades and is a major contributor to pathologies generated under
conditions of oxidative stress. Immunohistochemical analysis confirmed the presence
of 4-HNE within the liver tissue of both nrf2-/- and WT livers that were treated with 5
mg/kg PFOS or 5 mg/kg PFOA. Fig. 30 shows the control nrf2-/- and WT livers that
exhibit no sign of lipid peroxidation. Fig. 31 & 32 shows the accumulation of brown
pigmentation which represents 4-HNE in liver tissue, especially, around the portal triad
and central vein in nrf2-/- and WT animals that were treated with PFOS and PFOA.
3.2.6 GSH/GSSG ratio in the liver
PFOS and PFOA treated WT mice showed alterations in the GSH/GSSG ratios. Total
glutathione (reduced and oxidized glutathione) and oxidized glutathione levels were
measured and the ratio was calculated. Fig. 33 demonstrates that the liver of WT mice
treated with PFOS (5 mg/kg) or PFOA (5 mg/kg) caused significant increases in the
GSH/GSSG ratios when compared to the WT control group (Fig. 33). Nrf2-/- animals
did not show any significant increases in the GSH/GSSG ratios as compared to control
nrf2-/- animals.
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3.2.7 Brain Microscopy: Hematoxylin and Eosin Staining
Light microscopy was used to observe the brain hippocampal tissues of PFOS
and PFOA treated groups and those of the control mice that were stained with
hematoxylin and eosin stain. Control nrf2-/- and WT brain tissues, specifically dentate
gyrus of the hippocampus, had normal morphology (Fig. 34). PFOS and PFOA treated
nrf2-/- and WT animals demonstrated no significant differences when they compared
to the respective untreated controls (Fig. 35 & 36)
3.2.8 TUNEL Staining of the Hippocampus (Dentate Gyrus)
The TUNEL assay was used to determine apoptotic cells in the dentate gyrus of
the hippocampus. Control cells showed no TUNEL positive cells (Fig 37). Nrf2-/- and
WT animals treated with 5 mg/kg PFOS or 5 mg/kg PFOA showed no differences as
compared to the controls (Figs. 38 and 39). Apoptotic cells were quantified by blindly
counting TUNEL positive cells in 10 random fields at 40x by two independent
counters.
3.2.9 Lipid peroxidation : 4HNE staining of the Hippocampus
Fig. 40 shows the control nrf2-/- and WT brain (dentate gyrus of the
hippocampus) that exhibits no signs of lipid peroxidation. Also, Fig. 41 & 42 that
represent the PFOS and PFOA treated nrf2-/- and WT brain shows no 4HNE staining
as compared to the controls.
3.2.10 GSH/GSSG ratio in the Hippocampus
Brain tissue in neither the WT nor nrf2-/- treated animals with 5 mg/kg PFOS and 5
mg/kg PFOA showed any significant changes in GSH/GSSG ratios as compared to
respective untreated control animals (Fig. 43).
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Figure 3. Cytotoxic effect of PFOS and PFOA exposure on WT and nrf2-/- cells
using the Lactate Dehydrogenase (LDH) Assay. The levels of LDH release were
significantly higher in WT astrocytes treated with concentrations of 300 µM or 600
µM PFOS or 800 µM or µM PFOA for 24 hrs when compared to control WT cells as
indicated in (A) and (B), respectively. LDH release in Nrf2-/- astrocytes treated with
150-600 µM PFOS or 800 or 1000 µM PFOA for 24 hrs. was significantly higher
than control nrf2-/- control astrocytes as indicated in (A) and (B), respectively. LDH
release in nrf2-/- astrocytes was significantly higher than comparable doses in WT
astrocytes at 150-600 µM PFOS or 800 or 1000 µM PFOA. The experiment was
repeated in triplicate, n=4. Two-way analysis of variance (ANOVA) followed by
Bonferroni post-hoc test. (*) indicates significant difference in nrf2-/- groups as
compared to respective WT groups. (†) indicates significant difference in WT groups
as compared to WT control group. (#) indicates significant difference in nrf2-/treatment groups as compared to nrf2-/- control group.( †P < 0.05, †††,***,### P < 0.001)
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Figure 4. Cytotoxic effect of PFOS and PFOA exposure on WT and nrf2-/- cells
using the Neutral Red (NR) Assay. The levels of NR were significantly decreased in
WT astrocytes treated with concentrations of 150 µM, 300 µM or 600 µM PFOS or 800
µM or µM PFOA for 24 hrs when compared to control WT cells as indicated in (A) and
(B), respectively. NR levels in nrf2-/- astrocytes treated with 150-600 µM PFOS or 800
or 1000 µM PFOA for 24 hrs. was significantly lower than control nrf2-/- control
astrocytes as indicated in (A) and (B), respectively. NR levels in nrf2-/- astrocytes was
significantly lower than comparable doses in WT astrocytes at 300 or 600 µM PFOS or
800 or 1000 µM PFOA. The experiment was repeated in triplicate, n=4. Two-way
analysis of variance (ANOVA) followed by Bonferroni post-hoc test. (*) indicates
significant difference in nrf2-/- groups as compared to respective WT groups. (†)
indicates significant difference in WT groups as compared to WT control group. (#)
indicates significant difference in nrf2-/- treatment groups as compared to nrf2-/- control
group.( †P < 0.05, ††,**, ##P < 0.01, ### P < 0.001)
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Figure 5. Phase contrast light micrograph of nrf2-/- and WT astrocytes treated
with 75 and 600µM PFOS for 24 hrs. (A) Controls of nrf2 -/- and WT astrocytes
appear tightly compact with normal morphology, such typical fusiform elongated
projections with well-defined nucleus and cells evenly distributed on the culture field.
(B) Astrocytes treated with low concentrations of PFOS (75 µM) appeared similar to
control and observed decreases in cell density are consistent with cytotoxicity results.
(C) 600 µM PFOS showed alterations in cellular morphology, such as rounded cells
with retraction of cell processes as indicated by the black arrows and cell debris as
indicated by the white arrows. Decreases is cell density are consistent with
cytotoxicity results. Total magnification, x100.
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Figure 6. Phase contrast light micrograph of nrf2-/- and WT astrocytes treated
with 400 and 800µM PFOA for 24 hrs. (A) Controls of nrf2-/- and WT astrocytes
appear tightly compact with normal morphology, such as typical fusiform elongated
projections with well-defined nucleus and evenly distributed on the culture field. (B)
Astrocytes treated with low concentrations of PFOA (400 µM) appeared similar to
control. Decreases in cell density are consistent with cytotoxicity results. (C) 800 µM
PFOA showed alterations in cellular morphology, such as rounded cells with retraction
of cell processes as indicated by the black arrows and cell debris as indicated by white
arrows. Decreases in cell density are consistent with cytotoxicity results. Total
magnification, x100.
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Figure 7. Caspase 3 activity in nrf2-/- and WT astrocytes was induced
after PFOS and PFOA exposure. The activity of caspase 3 was significantly
increased in nrf2-/- and WT astrocytes treated with PFOS (600 µM) or PFOA
(800 µM) for 24 hrs. as compared to the controls that are indicated in (A) and
(B), respectively. Nrf2-/- astrocytes showed a significant increase in caspase
3 activity as compared to the respective WT astrocytes. The experiment was
repeated in triplicate, n=3. Two-way analysis of variance (ANOVA) followed
by Bonferroni post-hoc test. "(*) indicates statistically significant difference
in nrf2-/- groups as compared to respective WT groups. (†) indicates
significant difference in WT groups as compared to WT control group. (#)
indicates significant difference in nrf2-/- groups as compared to nrf2-/control group. (*, †,# P < 0.05 )
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Figure 8. TUNEL positive cells (apoptotic cells) were induced in nrf2-/astrocytes and WT astrocytes after PFOS and PFOA exposure for 24 hrs.
Control nrf2-/- and WT Astrocytes morphologically appeared normal with intact
nucleus and well defined cell processes. PFOS (600 µM) or PFOA (800 µM) treated
nrf2-/- and WT astrocytes for 18 hours showed positive apoptotic cells that are
characterized by a dark brown nucleus or whole cells that appear brown as indicated
by the black arrows. Total mag at 200x. n=3
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B

Figure 9. TUNEL positive control. A positive control (female rodent mammary
gland) was carried out with the TUNEL assay. Positive staining is indicated by the
black arrows.
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Figure 10. Quantification of TUNEL positive cells (apoptotic cells) induced in
nrf2-/- astrocytes and WT astrocytes after PFOS and PFOA exposure for 24
hrs. Apoptotic cells were quantified by blind counting of positive cells in 20
random fields by two independent counters. A significantly higher number of
apoptotic cells was counted after treatment with PFOS (600 µM) or PFOA (800
µM) in both cell types. Nrf2-/- astrocytes showed significantly higher numbers of
apoptotic cells as compared to the respective WT astrocytes. The experiment was
repeated in triplicate, n=3. Two-way analysis of variance (ANOVA) followed by
Bonferroni post-hoc test. (*) indicates significant difference in nrf2-/- groups as
compared to respective WT groups. (†) indicates significant difference in WT
groups as compared to WT control group. (#) indicates significant difference in
nrf2-/- groups as compared to nrf2-/- control group. ( * P < 0.05, †††,***,### P <
0.001)
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Figure 11. Levels of ROS were significantly increased in PFOS and PFOA
treated nrf2-/- and WT astrocytes. Levels of ROS were significantly higher in
nrf2-/- and WT astrocytes treated with PFOS (600 µM) or PFOA (800 µM) for 24
hrs. as indicated in (A) and (B), respectively. TBHP (200 µM) was used in the
experiment as a positive control. The experiment was repeated in triplicate, n=3.
Two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc test. (*)
indicates statistically significant difference in nrf2-/- groups as compared to
respective WT groups. (†) indicates significant difference in WT groups as compared
to wild type control group. (#) indicates significant difference in nrf2-/- groups as
compared to nrf2-/- control group. ( *, †,#P < 0.05, **P < 0.01)
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Figure 12. BHT pretreatment in nrf2-/- and WT astrocytes against
oxidative stress followed by PFOS and PFOA exposure. The BHT
pretreatment showed significant protection in WT astrocytes after exposure to
PFOS (300 µM) or PFOA (800 µM) for 24 hrs. but no significance was
observed in nrf2-/- astrocytes. The experiment was repeated in triplicate, n=3.
One-way ANOVA followed by Tukey’s multiple comparison’s post-hoc test.
(*) indicates significant difference in PFOS and PFOA treated astrocytes as
compared to their control groups. (#) indicates statistically significant
difference in BHT pretreated astrocytes as compared to PFOS or PFOA treated
cells. (*,#P < 0.05, **P < 0.01)
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Figure 13. The levels of lipid peroxidation were significantly increased in
PFOS and PFOA treated nrf2-/- and WT astrocytes. The levels of lipid
peroxidation were significantly higher in nrf2-/- and WT astrocytes treated with
PFOS (600 µM) or PFOA (800 µM) for 24 hrs. as indicated in (A) and (B),
respectively. The experiment was repeated in triplicate, n=3. Two-way analysis
of variance (ANOVA) followed by Bonferroni post-hoc test. (*) indicates
significant difference in nrf2-/- groups as compared to respective WT groups. (†)
indicates significant difference in WT groups as compared to WT control group.
(#) indicates significant difference in nrf2-/- groups as compared to nrf2-/- control
group. (*,†,#P < 0.05, (**,††,##P < 0.01).
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Figure 14. GSH/GSSG ratio in nrf2-/- and WT astrocytes treated with PFOS
and PFOA. The levels of GSH/GSSG ratio were significant decreased in nrf2-/and WT astrocytes treated with PFOS (600 µM) or PFOA (800 µM) for 24 hrs.
as indicated in (A) and (B), respectively. The experiment was repeated in
triplicate, n=3. Two-way analysis of variance (ANOVA) or followed by
Bonferroni post-hoc test. (*) indicates statistically significant difference in nrf2/- groups as compared to respective WT groups. (†) indicates significant
difference in WT groups as compared to wild type control group. (#) indicates
significant difference in nrf2-/- groups as compared to nrf2-/- control group.
(*,†,#P < 0.05)
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Figure 15. TEM of control WT astrocytes and WT astrocytes treated with
600 µM PFOS and 800 µM PFOA for 24 hrs. Arrowhead indicates normal
mitochondria with intact membranes and well defined cristae as shown in panel
(B). Black arrow indicates abnormal mitochondria that are characterized by
swelling and absence of cristae as shown in panels (D) and (F). Original
magnifications at (A) X6,000. (B) Magnified object of panel (A), X50,000. (C)
X8000, (D) Magnified object of panel (C), X30,000. (E) X5000, (F) Magnified
object of panel (E), X15,000.

57

Figure 16. TEM of control nrf2-/- astrocytes and nrf2-/- astrocytes treated with
600 µM PFOS and 800 µM PFOA for 24 hrs. Arrowhead indicates normal
mitochondria with intact membranes and well defined cristae as shown in panel(B).
Black arrow indicates abnormal mitochondria that are characterized by swelling and
absence of cristae as shown in panels (D) and (F). Original magnifications at (A)
X2000. (B) Magnified object of panel (A), X20,000. (C) X2500. (D) Magnified object
of panel (C), X20,000. (E) X2000. (F) Magnified object of panel (E), X15,000.
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Figure 17. The weight of nrf2-/- & WT mice after PFOS and PFOA exposure.
(A) shows the weight of nrf2-/- animal that were dosed with 5 mg/kg PFOS or PFOA
for 15 days. PFOS treated nrf2-/- animals started to lose weight at day 11. PFOA
treated nrf2-/- animals started to lose weight at day 12 (B) indicates the weight of
WT animals that were exposed to 5 mg/kg of PFOS or 5 mg/kg PFOA for 30 days.
No significant difference was observed in treated WT animal weight as compared to
the control WT animal weight.
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Figure 18. The liver weight of nrf2-/- & WT mice after PFOS and PFOA
exposure. (A) shows the liver weight of nrf2-/- animal dosed with 5 mg/kg PFOS
or 5 mg/kg PFOA for 15 days. The PFOA treated nrf2-/- liver weight was
significantly increased as compared to the control nrf2-/- liver weight, while the
PFOS treatment group did not show significant changes. (B) shows the weight
of the liver of the WT animals that were exposed to 5 mg/kg of PFOS or 5 mg/kg
PFOA for 30 days. The liver weight significantly increased in both PFOA and
PFOS treatment groups as compared to the control WT group. N=7
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Figure 19. The brain weight of nrf2-/- & WT mice after PFOS and PFOA
exposure. (A) shows the brain weight of nrf2-/- animals dosed with 5 mg/kg
PFOS or 5 mg/kg PFOA for 15 days. (B) shows the brain weight of WT
animals dosed with 5 mg/kg PFOS or 5 mg/kg PFOA for 30 days. There were
no significant changes in brain weight in WT or nrf2 -/- animals with either
PFOA or PFOS treatments. N=7
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Figure 20. Light micrographs of hematoxylin & eosin stained control
livers of nrf2-/- and WT animals after treatment with vehicle control (50%
PEG 400). The control liver micrographs of nrf2-/- (Panel A) and WT (Panel
B) appeared typical with intact hepatocytes and well defined sinusoids and
portal triads. Original magnification at X400. n=5.
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Figure 21. Light micrographs of hematoxylin & eosin stained PFOS treated liver of
nrf2-/- and WT animals. Liver micrographs of 5 mg/kg PFOS exposed nrf2-/- mice for
15 days (Panel A) and WT mice for 30 days (Panel B) displayed several morphological
alterations, such as cytoplasmic vacuolation (white arrow), hepatocellular hypertrophy,
round cytoplasmic inclusions (black arrow), hemosiderin accumulation (slight brown
pigmentation) (white arrowhead), and inflammatory cells infiltration (black arrowhead).
Original magnification at X400. n=5
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Figure 22. Light micrographs of hematoxylin & eosin stained PFOA treated liver
of nrf2-/- and WT animals. Liver micrographs of 5 mg/kg PFOA exposed nrf2-/mice for 15 days (Panel A) and WT mice treated for 30 days (Panel B) displayed
several morphological alterations, such as cytoplasmic vacuolation (white arrow),
hepatocellular hypertrophy, dead cells (black arrow), hemosiderin accumulation
(slight brown pigmentation) (white arrowhead). Original magnification at X400. n=5
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Figure 23. Light micrographs of trichrome stained control liver of nrf2-/- and WT
animal after treatment with vehicle control (50% PEG 400). The control
micrographs of nrf2-/- and WT liver appeared typical with intact hepatocytes and welldefined sinusoid and portal triad. Original magnification at X400. n=5
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Figure 24. Light micrographs of trichrome stained PFOS treated liver of nrf2-/and WT animal. Liver micrographs of 5 mg/kg PFOS treated nrf2-/- mice for 15 days
(Panel A) and WT mice for 30 days (Panel B) displayed several morphological
alterations, such as cytoplasmic vacuolation (white arrow), hepatocellular
hypertrophy, dead cells (black arrow), and fibrosis indicated by the blue stain (black
arrowhead). Original magnification at X400. n=5
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Figure 25. Light micrographs of trichrome stained PFOA treated liver of
nrf2-/- and WT animal. Liver micrographs of 5 mg/kg PFOA treated nrf2-/- mice
for 15 days (Panel A) and WT mice for 30 days (Panel B) displayed several
morphological alterations, such as cytoplasmic vacuolation (white arrow),
hepatocellular hypertrophy, dead cells (black arrow), and fibrosis as indicated by
the blue stain (black arrowhead). Original magnification at X400. n=5
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Figure 26. Light micrograph of TUNEL apoptotic cells in control liver of nrf2-/and WT animal treated with vehicle control (50% PEG 400). Control liver of nrf2/- (Panel A) and control liver of WT (Panel B) shows no indication of the presence of
apoptotic cells. Hematoxylin stain was used as a background stain. Original
magnification at X400. n=4
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Figure 27. Light micrograph of TUNEL apoptotic cells in PFOS treated liver of
nrf2-/- and WT animal. Liver micrographs of 5 mg/kg PFOS treated nrf2-/- mice for
15 days (panel A) and WT mice for 30 days (Panel B). Positive apoptotic cells have a
dark brown nucleus or the whole cell appears brown as indicated by the black arrows in
liver micrographs of nrf2-/- (Panel A) and WT (Panel B). Hematoxylin stain was used
as a background stain. Original magnification at X400. n=4
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Figure 28. Light micrograph of TUNEL apoptotic cells in PFOA treated liver of
nrf2-/- and WT animal. Liver micrographs of 5 mg/kg PFOA treated nrf2-/- mice for
15 days (Panel A) and WT mice for 30 days (Panel B). Positive apoptotic cells have a
dark brown nucleus or the whole cell appears brown as indicated by the black arrows in
liver micrographs of nrf2-/- (Panel A) and WT (Panel B). Hematoxylin stain was used
as a background stain. Original magnification at X400. n=4

70

TUNEL Assay
Liver

The number of apoptotic
cells per 10 fields

15

#
*

10

WT
nrf2-/-

5
0

)
g/
m
PF

PF

O

O

S

A

(5

(5

Co

m

nt

g/

kg

kg

ro
l

)

-5

Figure 29. Quantification of TUNEL apoptotic cells in liver of nrf2-/- and WT
animals after PFOS and PFOA exposure. Positive apoptotic cells were quantified
by blind counting of positive apoptotic cells in 10 random fields at 40x by two
independent counters. Apoptotic cells were significantly higher after treatment with
and PFOA (5 mg/kg), while no significant difference was observed in the PFOS (5
mg/kg) treated group. Nrf2-/- astrocytes showed significantly higher numbers of
apoptotic cells as compared to the respective WT astrocytes in PFOA treated group.
Two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc test. (*)
indicates statistically significant difference in nrf2-/- groups as compared to
respective WT groups.(#) indicates significant difference in nrf2-/- groups as
compared to nrf2-/- control group. ( #,* P < 0.05)
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Figure 30. Light micrograph of immunohistochemical stained for 4-HNE in
control liver of nrf2-/- and WT animals treated with vehicle control (50%
PEG 400). (A) represents control nrf2-/- liver. (B) represent control WT. No
indication of 4-HNE staining. Hematoxylin stain was used as a background stain.
Original magnification at X400. n=5.
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Figure 31. Light micrograph of immunohistochemical stain for 4-HNE in
PFOS treated liver of nrf2-/- and WT animal. Liver micrographs of 5 mg/kg
PFOS treated nrf2-/- mice for 15 days (panel A) and WT mice for 30 days (panel B).
Brown stain represents the accumulation of 4HNE, lipid peroxidation products, is
indicated by the black arrow. Hematoxylin stain was used as a background stain.
Original magnification at X400. n=5
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Figure 32. Light micrograph of immunohistochemical stain for 4-HNE in
PFOA treated liver of nrf2-/- and WT animal. Liver micrographs of 5 mg/kg
PFOA treated nrf2-/- mice for 15 days (panel A) and WT mice for 30 days (panel
B). Brown stain represents the accumulation of 4HNE, lipid peroxidation products,
is indicated by the black arrow. Hematoxylin stain was used as a background stain.
Original magnification at X400. n=5
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Figure 33. GSH/GSSG ratio in liver of nrf2-/- and WT animal treated
with PFOS and PFOA. The GSH/GSSG ratio were not significantly
increased in the liver of nrf2-/- animals treated for 15 days with PFOA or
PFOS (5 mg/kg) as compared to control nrf2-/- group. The GSH/GSSG
ratios were significantly increased in WT liver treated for 30 days with
PFOA (5 mg/kg) or PFOS (5 mg/kg) as compared to control WT group.
There was also significant increases in the levels of GSH/GSSG ratio in
PFOS and PFOA treated WT group as compared to the respective nrf2-/. (*,†,#P < 0.05).
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Figure 34. Light micrographs of hematoxylin & eosin stained control dentate
gyrus of nrf2-/- and WT animals after treatment with vehicle control (50%
PEG 400). The control dentate gyrus micrographs of nrf2-/- (Panel A) and WT
(Panel B) showed similar morphology and structure. Dentate Gyrus (DG),
Molecular Layer (ML), Granular Cells Layer (GCL), Subgranular Zone. Original
magnification at X400. n=5
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Figure 35. Light micrographs of hematoxylin & eosin stained PFOS
treated dentate gyrus region of the hippocampus of nrf2-/- and WT
animals. dentate gyrus. micrographs of 5 mg/kg PFOS treated nrf2-/- mice
for 15 days (Panel A) and WT mice for 30 days (Panel B) showed no
morphological alterations as compared to the controls in Figure 22. Dentate
Gyrus (DG), Molecular Layer (ML), Granular Cells Layer (GCL),
Subgranular Zone. Original magnification at X400. n=5
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Figure 36. Light micrographs of hematoxylin & eosin stained PFOA treated
dentate gyrus of nrf2-/- and WT animals. Dentate gyrus micrographs of 5 mg/kg
PFOA treated nrf2-/- mice for 15 days (Panel A) and WT mice for 30 days (Panel
B) showed no specific morphological alterations as compared to the controls in
Figure 22. Dentate Gyrus (DG), Molecular Layer (ML), Granular Cells Layer
(GCL), Subgranular Zone. Original magnification at X400. n=5
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Figure 37. Light micrograph of TUNEL apoptotic cells in control
dentate gyrus of nrf2-/- and WT animal treated with vehicle control
(50% PEG 400). (A) represents control nrf2-/- hippocampus (Dentate
Gyrus). (B) represent control WT hippocampus (Dentate Gyrus). No
TUNEL positive cells were observed in either animal. Dentate Gyrus (DG),
Molecular Layer (ML), Granular Cells Layer (GCL), Subgranular Zone.
Total mag at 400x. n=4
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Figure 38. Light micrograph of TUNEL apoptotic cells in PFOS treated
dentate gyrus of nrf2-/- and WT animal treated. Hippocampus (Dentate Gyrus)
micrographs of 5 mg/kg PFOS treated nrf2-/- mice for 15 days (Panel A) and WT
mice for 30 days (Panel B). No TUNEL positive cells were observed in either
animal. Dentate Gyrus (DG), Molecular Layer (ML), Granular Cells Layer (GCL),
Subgranular Zone. Original magnification at X400. n=4
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Figure 39. Light micrograph of TUNEL apoptotic cells in PFOA treated dentate
gyrus of nrf2-/- and WT animal treated. Hippocampus (Dentate Gyrus)
micrographs of 5 mg/kg PFOA treated nrf2-/- mice for 15 days (Panel A) and WT
mice for 30 days (Panel B). No TUNEL positive cells were observed in either
animal. Dentate Gyrus (DG), Molecular Layer (ML), Granular Cells Layer (GCL),
Subgranular Zone. Original magnification at X400. n=4
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Figure 40. Light micrograph of immunohistochemical stained 4-HNE in control
dentate gyrus of nrf2-/- and WT animal after treated with vehicle control (50%
PEG 400). (A) represents control nrf2-/- hippocampus (dentate gyrus). (B) represent
control WT hippocampus (dentate gyrus). No accumulation of 4HNE, lipid
peroxidation product, is shown in control nrf2-/- mice (panel A) and control WT mice
(panel B). Dentate Gyrus (DG), Molecular Layer (ML), Granular Cells Layer (GCL),
Subgranular Zone. Original magnification at X400. n= 5
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Figure 41. Light micrograph of immunohistochemical stained 4-HNE in PFOS
treated brain of nrf2-/- and WT animal. Hippocampus (Dentate gyrus) micrographs
of 5 mg/kg PFOS treated nrf2-/- mice for 15 days (panel A) and WT mice for 30 days
(panel B). No indication of lipid peroxidation product (4HNE). Dentate Gyrus (DG),
Molecular Layer (ML), Granular Cells Layer (GCL), Subgranular Zone. Original
magnification at X400. n=5
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Figure 42. Light micrograph of immunohistochemical stained 4-HNE in
PFOA treated dentate gyrus of nrf2-/- and WT animal. Hippocampus
(Dentate gyrus) micrographs of 5 mg/kg PFOA treated nrf2-/- mice for 15 days
(panel A) and WT mice for 30 days (panel B). No indication of lipid peroxidation
product (4HNE). Dentate Gyrus (DG), Molecular Layer (ML), Granular Cells
Layer (GCL), Subgranular Zone. Original magnification at X400. n=5
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Figure 43. GSH/GSSG ratio in brain of nrf2-/- and WT animal treated with
PFOS and PFOA. WT and nrf2 -/- animals treated with PFOA and PFOS (5
mg/kg) showed no significant alterations in GSH/GSSG ratios in brain as
compared to respective untreated control groups.
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4. DISCUSSION
The group of compounds known as Perfluoronated Substances (PFA) have
become pervasive in our environment, with detectable levels demonstrated in humans
and animals. While these compounds have been used and studied since the 1950s,
human toxicity has been reported in the last few years. Prefluorooctonoic Acid (PFOA)
and Perfluorooctonoic sulfonate (PFOS) have become two of the more widely studied
of the eight-carbon compounds in the group due to their prevalence and toxicity. The
current study investigated the toxicity of PFOS and PFOA in both in vitro and in vivo
models by using C57BL/6 mice wildtype mice and mice that are deficient in Nrf2, a
critical transcription factor responsible for translation of some of the most important
antioxidant enzymes mammal possess. Astrocytes from the hippocampus of these
animals were cultured to carry out the in vitro experiments in the study. The endpoints
for both the in vitro and in vivo studies related to formation of reactive oxygen species,
oxidative stress, and apoptosis. Since the hippocampus is one of the most susceptible
regions in the brain to a number of chemicals and is subject to several pathological
conditions (Kim et al., 2015), nrf2-/- and WT astrocytes were isolated and used as in
vitro models to determine the toxicity of PFOS and PFOA in this area of the brain.
The absorption of PFAS across the blood brain barrier (BBB) and cerebral
spinal fluid barrier have been met with some skepticism, however, a number of
epidemiologic studies have found levels of PFOS and PFOA in brain and cerebrospinal
fluid (CSF) samples (Maestri et al., 2006; Wang et al., 2018). A study by Yu et al.
(2020) observed astrocytic dysfunction when ICR mice were dosed with PFOS (Yu et
al., 2020).
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The purpose of including nrf2-/- cells along with WT cells is to appropriately
delineate the oxidative stress status and cytotoxicity of PFOS and PFOA exposure. The
results of the cell viability and altered cellular morphology illustrated that the reduction
in astrocyte viability and the morphological changes were dose-dependent effects of
PFOS and PFOA. The concentrations of PFOS and PFOA used in this study were
chosen based on relevant concentrations used in previous studies (Florentin et al.,
2011). The LDH cytotoxicity assay was chosen to assess the cytotoxic effects of PFOS
and PFOA in this current investigation. Damage to the cell membrane after chemical
exposure is indicated by increased levels of LDH released into the extracellular space.
Evaluation of the LDH cytotoxicity assay data indicates that cytotoxicity increased in
a dose-dependent manner when mouse hippocampal nrf2-/- and WT astrocytes were
exposed to PFOS and PFOA for 24 hours. The cytotoxicity was significantly increased
in 150 µM, 300 µM, or 600 µM PFOS treated nrf2-/- astrocytes as compared to nrf2-/control astrocytes. However, only 300 µM, and 600 µM PFOS treated WT cells showed
significant increases in cytotoxicity as compared to WT control astrocytes. PFOA
exposure caused LDH release that was significantly higher in nrf2-/- astrocytes treated
with 800 µM or 1000 µM PFOA as compared to nrf2-/- astrocytes control. WT
astrocytes that were exposed to the same concentrations of PFOA have a significant
increase (P<0.05, P<0,001) in LDH release compared to WT control astrocytes. In
PFOS and PFOA exposure, nrf2-/- astrocytes have significantly higher (P<0.05,
P<0,001) cytotoxicity (PFOS treatments of 150 µM, 300 µM, or 600 µM ) and (PFOA
treatments of 800 µM or 1000 µM) as compared to respective WT astrocytes (Fig. 3)
suggesting the important of antioxidant defenses in the toxicity of these agents. Neutral
red is a viability assay that measures cell viability based on the amount of neutral red
take up by lysosomes in viable cells. The exposure to PFOS (150 µM, 300 µM, or 600
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µM) or PFOA (800 µM or 1000 µM) showed significant decreased in nrf2-/- and WT
astrocytes as compared to the controls. Additionally, PFOS (300 µM or 600 µM) or
PFOA (800 µM or 1000 µM) treated nrf2-/- astrocytes have significant decreases in
neutral red uptake as compared to treated WT groups (Fig. 4). The viability results were
consistent with the previous in vitro study in which Florentin and colleagues (2011),
using human HepG2 as a model, illustrated that significant decreases in the cell viability
were observed at doses of PFOS (300 µM, 400 µM, or, 600 µM) or PFOA (200 µM,
400 µM, 600 µM, or 800 µM) (Florentin et al., 2011). Another study by Zarei et al.
(2018) observed significant reduced viability levels in human lymphocytes at doses of
200 µM, 300 µM, 400 µM, or 500 µM PFOS (Zarei et al., 2018). Based on our study,
it appears that PFOS showed more toxicity as compared to PFOA. The difference in
toxicity is most likely due to the difference in chemical structure as both PFOS and
PFOA share the same backbone (eight carbons bonded with fluorine) but different
additional groups, sulfonic acid in PFOS and carboxylic acid in PFOA (Lau et al.,
2004). Further investigations is necessary to study the involvement of these functional
groups in the toxicity of PFOS and PFOA.
Alterations in cellular morphology were examined by using phase-contrast light
microscopy after 24 h exposure to serum-free media, PFOS and PFOA. The control
nrf2-/- and WT astrocytes exhibited characteristic morphology, such as typical fusiform
elongated projections, smooth plasmalemma, well-defined nuclei and cells evenly
distributed on the culture field (Fig. 5A & 6A). Nrf2-/- and WT astrocytes treated with
low concentration of 75 µM PFOS appeared similar to the control cells and exhibited
no obvious morphological changes, although micrographs are consistent with decreases
in cell number indicated in the cytotoxicity data (Fig. 5B). However, nrf2-/- and WT
astrocytes treated with PFOS at high concentration (600 µM) showed morphological
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alterations such as rounded cells, retraction of cell processes, cellular debris, and
shrinkage of cells (Fig. 5C). At the low concentration of PFOA (400 µM) there were
no obvious morphological changes observed. The density of cells at this concentration
however was consistent with losses in viability data (Fig. 6B). In contrast, nrf2-/- and
WT astrocytes treated with PFOA at the high concentration (800 µM) showed abnormal
morphology, including rounded cells with retraction of cell processes and cellular
debris (Fig. 6C). The results of the microscopic observations were consistent with
reduced viability results obtained in the LDH cytotoxicity and neutral red assays. Based
on the cytotoxicity data, 75 µM or 600 µM of PFOS or 400 µM or 800 µM of PFOA
were chosen as low and high doses to conduct further experiments.
Apoptosis is one of the mechanisms of cell death that was investigated in the
current study. Caspases play an essential role in programmed cell death. Caspase-3 (an
executioner caspase) is one of the caspases that mediates apoptosis and is routinely
measured as a biomarker of this process. It was shown that the activity of caspase-3
was significantly higher in nrf2-/- and WT astrocytes after exposure to high
concentration of PFOS (600 µM) or PFOA (800 µM) as compared to untreated cells
(Fig. 7). However, the low doses, 75 µM or 400 µM, of PFOS and PFOA, respectively,
showed no significant changes (Fig. 7). At high concentrations of PFOS or PFOA, the
activities of caspase 3 in nrf2-/- astrocytes were significantly higher than the respective
WT astrocytes (Fig. 7). Various cell lines examined by other investigators also showed
increases in apoptosis following exposure to these compounds. Xu et al., (2019)
concluded that PFOS and PFOA significantly enhanced the apoptotic pathway of
C57BL/6J mouse primary hepatocytes which supports the method of cell death
determined in our study (Xu et al., 2019). In another study, SH-SY5Y cells showed
increases in cleaved-caspase 3 levels after 50 µM, 100 µM, 200 µM PFOS exposure
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which further supports the findings of the present work (Sun et al., 2018). Kraugerud
et al., (2011) demonstrated that the cytotoxic response of H295R cells to PFOS and
PFOA was mainly via apoptosis. Additionally, the increases in caspase 9 and caspase
3 after exposure of N9 microglia cells to PFOS supports that apoptosis was typically
induced via the intrinsic pathway (Zhang et al., 2011)
In the current study, apoptotic cells were visualized and quantified via using the
TUNEL assay (Fig. 8 & 10). High concentrations of PFOS or PFOA resulted in
significant numbers of apoptotic cells that were quantified by blindly counting
apoptotic cells in 20 random fields. Significantly higher apoptotic cells were observed
in treated nrf2-/- astrocytes as compared to matched treated WT astrocytes. Nrf2-/astrocytes exhibited poor adherence to chambers at the 24h chemical exposure in the
TUNEL assay due to the coating used in the cell chambers and the number of washes
required in the procedure. Initial testing at the 24 hr. time point resulted in nrf2 -/- cells
being almost completely washed away, therefore, the time period of chemical exposure
had been lowered to 18 hours in order to pursue the experiment while maintaining cell
adherence. Even at the lowered time point, effects to the nrf2 -/- cells was significantly
greater than effects seen in the WT cells.
Excessive production of ROS plays an important role in lipid peroxidation,
GSH/GSSG ratio, and the apoptotic pathway (Fig 11, 13, 14). ROS are critical
mediators for cellular apoptosis through mitochondrial dysfunction. Accordingly,
extreme ROS production has been implicated in neurotoxicity. The current work
demonstrated that 24h exposure to 600 µM PFOS or 800 µM PFOA significantly
increased ROS levels, elevated lipid peroxidation (Fig. 13), and decreased GSH/GSSG
ratio (Fig. 14) in nrf2-/- and WT astrocytes. These alterations were significantly
exacerbated in nrf2-/- astrocytes. In support of our results on ROS production, Wielsøe
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et al. (2015) found a remarkable increase in levels of ROS after HepG2 cells were
exposed to PFOS or PFOA. A study by Tang et al. (2018) showed that PFOA elevated
lipid peroxidation in Carassius auratus lymphocytes which correlated well with the
findings of our study.
The present study showed a decreased GSH/GSSG ratio which is indicative of
oxidative insult. Liu et al. (2007) investigated the effect of PFOS on primary cultured
hepatocytes of fresh water tilapia (Oreochromis niloticus) and found that PFOS caused
significant depletion of glutathione. Our data demonstrates that the GSH/GSSG ratio
decreases significantly in the 600µM PFOS or 800µM PFOA exposure groups, a
finding that correlates well with increases in ROS demonstrated in (Fig. 11) in the same
groups. Further, the ratios are significantly more depressed in the nrf2-/- cells then WT
cells, which is not surprising considering the greatly diminished ability of these cells to
produce GSH.
Formation of ROS can occur in different sub-cellular organelles but the most
common source of ROS formation intracellularly are mitochondria (Kelly et al., 1998).
In addition, mitochondria can be adversely affected by oxidative stress. Several studies
have shown that mitochondria may be a subcellular target for PFOS. Hu and Hu, (2009)
illustrated that the effect of PFOS and PFOA on Hep G2 cells showed reduction of
mitochondrial membrane potential (MMP), increases in Bcl-2, and increases in p53
resulting in dysfunction of the mitochondria (Hu and Hu, 2009). In our study, TEM was
used to investigate adverse mitochondrial alterations after exposure to 600 µM PFOS
or 800 µM PFOA in nrf2-/- and WT astrocytes (Fig. 15 & 16). Clear damage to the
cells occurred, especially the mitochondria which appeared grossly swollen with a
complete loss of cristae after PFOS and PFOA treatment.
Butylated hydroxytoluene (BHT) is a lipophilic organic compound that has
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antioxidative properties. The mechanism by which BHT exerts its antioxidant activity
involves quenching of reactive oxygen species and lipid soluble radicals. The
antioxidant ability of BHT may also arise through synergistic effects that increases the
capability for nrf2-regulated endogenous antioxidants to operate (Lambert et al., 1996).
The chemicals in this study have shown increases in ROS levels, therefore, utilizing
BHT as an antioxidant provides further evidence of ROS involvement. Nrf2-/- and WT
astrocytes were pretreated 24 hours with BHT and exposed to 300 µM PFOS or 800
µM PFOA (Fig. 12). BHT pretreatment did not offer any significant protection against
PFOS and PFOA in nrf2-/- astrocytes although there was a non-significant decrease
in ROS levels with BHT pretreatment. We speculate that the toxicity of PFOS and
PFOA at those concentrations overwhelmed the protection potential of BHT in these
cells. The data showed that WT astrocytes responded to BHT pretreatment and the ROS
levels were significantly decreased. The reduction of Nrf2 in nrf2-/- astrocytes
apparently disabled their ability to significantly respond to BHT as is shown in WT
astrocytes. In WT astrocytes, the presence of Nrf2 supports the effect of BHT against
the oxidative stress resulting from the test agents. Similar results have been observed
in the literature when Zarei et al. (2018) demonstrated that BHT-pretreated human
lymphocytes resulted in a significant decrease in ROS after 300 µM PFOS exposure.
Toxicological investigations in adult research animals have shown that PFOS
and PFOA can lead to changes to the body and organs weight. Thyroid hormone is
among molecules that influences body weight. PFOS and PFOA were reported to
interfere with homeostasis of thyroid hormones which play a role in regulating body
weight (Lee and Choi, 2017; Liu et al., 2017). A prospective study reported an
association between human weight and both chemicals PFOS and PFOA which disrupt
body weight regulation and metabolism (Liu et al., 2017). However, Lai and colleagues
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(2018) dosed mice with 3 mg/kg PFOS for 7 weeks and the animal weight was not
significantly different from the control group (Lai et al., 2018).
Nrf2 plays an influential role in weight gain via regulating adipogenesis,
therefore; the absence of Nrf2 caused reduction in adipose tissue mass (Xue et al.,
2013). Nrf2-/- animals in our study were exposed to PFOS and PFOA for 15 days
leading to more weight loss as compared to WT animal (Fig. 17A). However, the
weight of WT mice was not shown to be significantly different from the control group
after 30 days being exposed to 5 mg/kg of either chemicals (Fig. 17B). In contrast, the
body weight of PFOS and PFOA treated nrf2-/- mice started to significantly decline on
day 11 in the PFOS treated group and on day 12 in the PFOA treated group. The weights
were continuously decreased in treated nrf2-/- mice until the last day of dosing (day 15)
(Fig. 17A). A number of studies stated that the absence of Nrf2 decreases the lipid mass
in the body (Pi et al., 2010; Xu et al., 2015). Additionally, the nrf2-deficient body is
susceptible to the chemical toxicity which eventually interrupts the metabolic
mechanisms, such as hormones that can ultimately result in weight loss (Xue et al.,
2013).
The Liver neutralizes a wide range of toxic chemicals, both those produced
internally and those coming from the environment. Previous studies have clearly
established a correlation between PFOS and PFOA exposure and their adverse impact
on liver mass by perturbing lipid metabolism and inducing liver steatosis (Tan et al.,
2013; Wang et al., 2013; Martin et al., 2007). A study by Wang (2013) showed that
PFOA interrupted the export of lipid from the liver of BALB/c mice treated with 5, 10,
or 20 mg/kg PFOA for 14 days (Wang et al., 2013). This interruption resulted in lipid
accumulation inside the liver and cause hepatic hypertrophy (Wang et al., 2013). PFOS
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has previously been shown to cause steatosis and increase triglyceride levels in the liver
(Haughom and Spydevold, 1992; Kudo & Kawashima, 1997). A study associated the
liver enlargement to the activation of peroxisome proliferator activated receptor alpha
(PPARα ) after exposure to PFOA (Schlezinger et al., 2020). In contrast, an
investigation by Yang et al, (2002) showed that liver weights increased in PPARα
deficient mice after being exposed to PFOA (Yang et al., 2002). In Yang (2002) study,
in spite of the decreased body weight, lipid accumulation was observed in PFOS and
PFOA-exposed hepatic tissue leading to hypertrophy. A similar result has been reported
in other related studies. KM mice exposed to 10 mg/kg PFOA for 14 days experienced
obvious hepatomegaly and induced a significant increase in liver weight (Yang et al.,
2014). In our study, the liver mass of PFOS and PFOA treated WT mice was significant
increased as compared to the WT control (Fig. 18B). However, only PFOA treated nrf2/- mice showed significant increase in liver mass (Fig. 18A). On the other hand, brain
weight did not show any difference between groups (Fig. 19).
The histopathological evaluation of this study revealed that the livers of PFOS
and PFOA treated nrf2-/- and WT mice showed morphological alterations, including
cytoplasmic vacuolization, round cytoplasmic inclusions, necrotic cells, hepatocellular
hypertrophy, inflammatory cells infiltration, fibrosis, and brown pigmentations that
may represent the precipitation of hemosiderin (Figs 20-25). The findings of this study
are consistent with previous studies. Xing et al, (2016) dosed C57BL/6J mice with 5 or
10 mg/kg PFOS for 30 days and found morphological changes to the livers, such as
vacuolization and hepatic hypertrophy. Another study by Qazi et al. (2013) reported
apoptotic cells in hematoxylin & eosin-stained liver tissues after treating C57BL/6 mice
with PFOS-mixed diet (daily intake is 6 ± 1.3 mg/kg/day).
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Lipid peroxidation is another indicator of oxidative stress. Previous studies have
shown that PFOA and PFOS cause increased ROS generation and oxidative DNA
damage in HepG2 cells (Eriksen et al., 2010; Yao et al., 2005) and increased
malondialdehyde (MDA) levels in cultured tilapia (Oreochromis niloticus) hepatocytes
(Liu et al., 2007). Another study by Kamendulis et al, (2014) exposed C57BL/6 mice
to 5 mg/kg PFOA for 7 days and detected increases in the lipid peroxidation product 8iso prostaglandin E2 (8-iso-PGF2) in the pancreas and liver. Consistent with these
results, we observed an accumulation in the lipid peroxidation product 4hydroxynonenal (4HNE) in the liver of 15 days treated nrf2-/- and 30 days treated WT
mice with PFOS or PFOA (Figs 30-32).
The literature data on the ratio of GSH/GSSG have been very limited. A study
by Kawashima (1994) exposed rats by allowing access to diet mixed with PFOA at a
concentration of 0.01% (w/w) for 26 weeks. The liver was removed and the findings
showed significantly decreased glutathione peroxidase and glutathione reductase.
However the glutathione content showed no difference from the control (Kawashima
et al., 1994). BABL/c male mice were treated with 5 or 20 mg/kg PFOA for 28 days
and showed significant decrease in glutathione peroxidase (GPx-1) in mouse
epididymis (Lu et al., 2016). In our study, the GSH/GSSG ratio in livers showed
significant increases in the treated nrf2-/- and WT mice as compared to their controls
(Fig. 33). However, the treated nrf2-/- groups were significantly reduced as compared
to the respective treated WT groups (Fig. 33).
TUNEL apoptotic cells were visualized in liver tissues of PFOS and PFOA
treated nrf2-/- and WT mice. The positive apoptotic cells were significantly higher in
PFOA treated nrf2-/- group as compared to the respective WT. Similar to our data, a
study showed that apoptotic cells were observed in liver cells from CD-1 mice treated
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with 1 or 10 mg/kg/day of PFOA and for 10 days (Wen et al., 2020). The nuclear
transcription factor Nrf2 is responsible for the upregulation of Bcl-2, antiapoptotic
protein, which play a role in protecting cells. The lack of nuclear transcription factor
Nrf2 leads to insufficient production of antiapoptotic protein; therefore, nrf2-/- model
would be more susceptible to the toxicity of the chemicals and cause an increase in the
number of apoptotic cells (Niture and Jaiswal, 2012). In spite of the apoptotic cells
being significantly higher in treated nrf2-/- as compared to the respective WT, the
GSH/GSSG ratio was notably decreased in nrf2-/- group as compared to the WT group
(Figs. 26-29). The high number of apoptotic cells in nrf2-/- group that were exposed to
PFOA suggests that the nrf2-/- animals may be unable to maintain the homeostasis in
oxidant-antioxidant activity. Consequently, the absence of Nrf2 increases the
susceptibility of the cells to oxidative stress resulting in cell death.
The effects of PFOS on adult brain and its potential mechanism remains unclear.
It is reported that PFOS exposure cause a deficit in spatial memory in adult male mice
(Fuentes et al., 2007) without disturbing motor and sensory function, general activity
and exploratory behavior. These data suggest that PFOS may cause deficits in some
brain areas such as hippocampus, which is the structure directly responsible for the
acquisition and the retention of spatial memory and especially vulnerable to damage
(Broadbent et al., 2004).
It is clear that PFOS and PFOA can penetrate the BBB because they have been
identified in the brain itself (Austin et al., 2003; Greaves et al., 2013; Pedersen et al.,
2015). Adult female Sprague-Dawley rats dosed with PFOS for two weeks had
detectable amounts of PFOS in a number of brain regions including the cortex,
hippocampus, brainstem, cerebellum, and hypothalamus (Austin et al., 2003). PFOS
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and PFOA have also been identified in polar bear brains (Greaves et al., 2013; Pedersen
et al., 2015) and in cerebrospinal fluid (Harada et al., 2007) and brain samples from
human patients (Maestri et al., 2006; Pérez et al., 2013). A study reported that some
apoptosis-related proteins, including caspase-3, Bcl-2, Bcl- XL and survivin
significantly changed in hippocampus, which played a role in the apoptosis of
hippocampal neural cells after C57BL6 mice were exposed to 10.75 mg/kg PFOS for 3
months. Cui et al., (2009) treated rats with 20 mg/kg PFOS or PFOA for 28 days and
the brain tissues showed no signs of gross histopathological changes but some
alterations, such as focal hyperplasia of cerebral gliocytes, dilatation and congestion in
inferior caval veins of cerebral arachnoid mater accompanied by slight focal
hemorrhage, broadened gap around veins and neurocytes, and focal demyelination of
nerve fibers, which were especially observed in the 20-mg/kg/day exposure groups (Cui
et al., 2009). In our study, the brain, especially dentate gyrus, has been microscopically
observed in 5 mg/kg PFOS or 5 mg/kg PFOA treated nrf2-/- and WT mice (Figs. 3436). The chemical treated nrf2-/- and WT dentate gyrus did not have gross
histopathological alterations as compared to the controls. In our study, histological
examination of brain tissues of the 5 mg/kg PFOS and 5 mg/kg PFOA dosed animals
were also evaluated. These data showed that brain tissues stained with hematoxylin &
eosin demonstrated no major morphological changes.
Lipid peroxidation product 4HNE (Figs. 40-42), GSH/GSSG ratio (Fig. 43), and
apoptosis detected via using TUNEL assay (Figs. 37-39) were also studied on the nrf2/- and WT brain. These are essential biomarkers that indicate the presence of oxidative
stress that leads to cell death. The chemical dose used in this study was 5 mg/kg. At
this dose, liver pathology was detected in both nrf2-/- and WT animals. However, the
hippocampus of these animals did not demonstrate any detectable changes.
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The animals used in this study were 7 week old adult mice in which the blood
brain barrier is mature and may interrupt the majority of absorption of these chemicals.
PFOS and PFOA have been detected in the brain with measurable levels (Austin et al.,
2003; Greaves et al., 2013; Pedersen et al., 2015). Most studies investigated the changes
to the levels of the neurotransmitters that might cause behavioral effects (Yu et al.,
2016; Foguth et al., 2019). Some studies (Johansson et al., 2009; Johansson et al., 2008;
Liu et al., 2009) used models with younger animals in which the blood brain barrier is
not fully matured so that the chemicals can easily distribute into the brain. In the current
work, limited studies were conducted and specific proteins were investigated. The
failure to yield morphological or biochemical changes in the hippocampus, may be a
consequence of the timing of the study, the age of the animals or the time at which
molecular markers might manifest to overt and observable toxicity in this area of the
brain. In the future, further research on the mechanisms of toxicity, especially the
oxidative stress in the brain, may clarify toxicity in this area.
In conclusion, this study demonstrated that exposure to PFOS an PFOA caused
toxicity in the in vitro models and in the in vivo models. The in vitro models were nrf2/- astrocytes and wild-type (WT) astrocytes. PFOS and PFOA were able to induce
oxidative stress and elevate apoptosis in nrf2-/- and WT astrocytes. Cell viability was
significantly decreased and cellular morphology showed morphological alterations due
to the toxicity of PFOS and PFOA. The levels of ROS, lipid peroxidation, and caspase
3 activity were significantly increased. The GSH/GSSG ratio was significantly
decreased. The mitochondria of nrf2-/- and WT astrocytes showed dramatic
morphological alterations, such as swollen mitochondria and loss of cristae.
Additionally, butylated hydroxytoluene (BHT), an exogenous antioxidant, decreased
the levels of the ROS and it showed a protective effect against the oxidative stress
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produced from the chemical exposure. Nrf2-/- astrocytes showed significant toxicity as
compared to WT astrocytes. Nrf2-/- and WT C57BL/6 mice, were also used to address
the toxicity of PFOS and PFOA as in vivo models. Brain and liver were removed as
target organs. Brain was chosen as to parallel the in vitro study to assess if effects to
hippocampus in live animals was comparable to cell culture. Liver was chosen as an
organ known to be affected by these agents with the goal to assess Nrf2 involvement in
each organ. Animal weights, hematoxylin & eosin stain, trichrome stain, GSH/GSSG
ratio, 4-hydroxynonenal (4HNE), and apoptosis were evaluated and demonstrated
significant changes from the control after exposure to PFOS and PFOA. However, the
hippocampus did not demonstrate any adverse effects using the methods employed in
this study. The comparison of the levels of toxicity between nrf2-/- and WT models
was a novel and important approach that validated the role of antioxidant defenses and
the importance of Nrf2 in its protective role against the oxidative stress resulting from
PFOS and PFOA toxicity.
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